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The effect of phytoestrogens on breast and prostate cancer cell lines – potential 
implications for bone preferential metastasis to bone 
Safaa Salman Mezban AL-Thamiree 
Abstract 
Many epidemiological studies indicate that diets rich in phytoestrogens (PE), 
especially soy and grain products, may be associated with a lower risk of some 
steroid hormone-dependent cancers such as breast and prostate. In particular 
PE have been shown to reduce the incidence of skeletal metastasis which have 
a high degree of morbidity and mortality. However, the most effective 
combinations of PEs and the mechanism through which they may reduce bone 
metastasis remain unclear. Therefore, this study aims to establish the most 
effective combinations of common dietary PE on breast and prostate cancer line 
proliferation, motility, and expression of genes implicated in disease progression 
and preferential metastasis to the skeleton. The potential modifying effect of 
cytokines that tumour cells are exposed to in the bone micro environment will 
also be studied including TGF-β, BMP7 and IL-33. 
Results showed that phytoestrogens genistein and daidzein significantly 
reduced prostate cancer cell viability (PC3 cells) with concentration 10-7 M 
(15 %, P = 0.01) and 10-6 M (11%, P = 0.04) for genistein and for daidzein the 
decrease in cell number was (18%, P value = 0.04) for 10-8 M and (22 %, P = 
0.01) for 10-7 M. In breast cancer cell line (MCF7) genistein and coumestrol 
showed a significant decrease in cell number while daidzein did not. The 
decrease in (MCF7) cell number with genistein was (15 %, P = 0.04) and (25 %, 
P = 0.04) for 10-6 M and 10-5 M respectively, while in coumestrol concentrations 
 
VI 
 
10-7 , 10-6  and 10-5 M showed the most significant decrease in cell number and 
were  (29 %, P = 0.03), (34 %, P= 0.01) and  (37%, value = 0.007) respectively. 
Motility results showed no significant reduction in the closure time of the scratch 
in both cell lines and there was an acceleration in the healing time of the scratch 
in both cell lines but was significant only in breast cell line (MCF7) with 
coumestrol after 6 ,12 and 24 hours at concentrations between (10-9 - 10-5  M). 
Non-selective oestrogen receptor modulator (ICI 182,780) abolishes the effect 
of genistein (10-7 and 10-6 M) and daidzein (10-8 and 10-7 M) reduction in cell 
viability and increased PC3 cell numbers significantly. In MCF7 cells, (ICI 
182,780) also abolished the effect of coumestrol and genistein and increased 
the cell numbers but not to a significant levels.  
While genistein, daidzein and coumestrol reduced breast and prostate cell 
viability individually in an oestrogen receptor dependent manner and this 
beneficial effect is lost when the effective concentrations are combined. 
Although, transforming growth factor β (TGFβ), shows antagonist effect on 
phytoestrogens induced changes when combined with (daidzein and genistein) 
and blocks any effect of PEs and increase collagen type I gene expression. In 
MCF7 cells, the non-inhibitory effect of individual genistein on PTHrP is lost in 
the presence of TGFβ but continues with significant decrease with snail. The 
non-inhibitory effect of coumestrol on PTHrP and snail genes expression altered 
to reduced significantly which suggest a strong effect of TGFβ on coumestrol 
and genistein action by interfering as a bone microenvironment cytokine. 
While bone morphogenic protein 7 (BMP7) had an inhibitory effect for the PEs 
(daidzein and genistein) and increased the expression of Runx2 in prostate 
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cancer cell line. In MCF7 cells, BMP7 inhibits the effect of (genistein and 
coumestrol) and increased the expression of snail to a high level. 
Interleukin-33 (IL-33), reverse the inhibitory individual effect of phytoestrogens 
on Runx2, CXCR4, snail and Integrin α5 gene expression in prostate and breast 
cancer cell lines. 
In conclusion, phytoestrogens are effective when administrated individually but 
lose their effect in combination with other phytoestrogens. Clinicians must 
consider the overall profile of phytoestrogens before administration. 
Epidemiologically, what applied to an area regarding the effect of 
phytoestrogens must not apply to other areas. Hence, administrating 
phytoestrogens at early ages might be of beneficial effect than in elder ages.  
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Chapter one: General introduction 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2 
 
1.1 General Introduction  
Cancer can be defined as an unregulated growth arising from one cell. The 
scientific or medical term for cancer is a malignant neoplasm, which is defined 
as an independent growth of tissue not subject to the basic regulation of normal 
growth and apoptosis that is able to invade local tissues and metastasise to 
distant sites.  
Cancer accounts for about 30% of all deaths in developed Western countries 
and one person out of three will be treated for cancer in their lifetime. As the 
incidence of most cancers rises with age, the number is expected to grow, if life 
expectancy continues to increase. If one considers the incidence and mortality 
by tissue type most are carcinomas which arise from epithelial tissue (Schulz, 
2005). Breast cancer in women and prostate cancer in men account for a 
significant proportion of carcinomas alongside those of the lung and large 
intestine. Less prevalent but still posing a substantial burden are carcinomas of 
the bladder, stomach, liver, kidney, pancreas, oesophagus, cervix and ovary. 
Each of these like breast and prostate display geographical differences in 
incidence (Schulz, 2005).  
1.2 Breast cancer 
Breast cancer is a complicated disease that displays distinct clinical, 
morphological and molecular subtypes (Eroles et al., 2012). Four basic types of 
breast cancer have been recognised (Luminal A, Luminal B, HER2-enriched, 
and basal-like) and a normal breast-like group (Prat & Perou, 2011; Sørlie et al., 
2001). The basal subtype is defined by the absence of ER, PR, and HER2 
expression and studies suggest that the triple negative and basal types may be 
synonymous(Vallejos et al., 2010) .  
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During the last decade, technological advances, in particular high throughput 
genomic analysis, suggest that the four subtype classification system is too 
simplistic (Eroles et al., 2012). Furthermore, even if a tumour initially displays a 
specific mutation that could be targeted, subsequent changes can lead to drug 
resistance as the disease progress (Eroles et al., 2012), generating additional 
molecular subtypes of breast cancer. A greater understanding of these 
molecular variants could enable the development of new therapeutics to target 
these resistant forms (Ashworth, 2008; Farmer et al., 2005). 
The concept that breast cancers are heterogeneous has led to the potential for a 
more personalized approach to prognosis and therapy to enable the best 
outcome (Eroles et al., 2012). Personalized therapy is already available for ER 
and HER2neu positivity, but additional specific therapeutic/screening plans have 
the potential to improve death rates (Rahib et al., 2014). For instance, a new 
breast cancer intrinsic subtype, known as Claudin-low, has been identified in 
human and, mouse tumours (Herschkowitz et al., 2007), and a panel of breast 
cancer cell lines (Prat et al., 2010). Clinically, the majority of Claudin-low 
tumours are poor prognosis ER-negative (ER-), PR-negative (PR-), and HER2-
negative (HER2-) (triple-negative) invasive ductal carcinomas with a high 
frequency of metaplastic and medullary differentiation. Data shows that they 
have a response rate to standard neoadjuvant chemotherapy (a cheomotherapy 
with other treatments given before breast cancer surgery) that is intermediate 
between Basal-like and Luminal tumours. Also, claudin-low tumours are 
enriched with unique biologic features linked to mammary stem cells (MaSCs), 
a main EMT signature, and show properties of tumour initiating cells (known as 
Cancer Stem Cells, CSCs) (Prat & Perou, 2011), the study of which is leading to 
the formulation of new hypothesis regarding the ‘cell of origin’ of the different 
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subtypes of breast. Furthermore, genes that are highly expressed in tumours 
with a poor prognosis are a possible target for the logical development of new 
drugs. Interestingly, rash gene (an early player in many signal transduction 
pathways to regulate cell division in response to growth factor stimulation) in 
both transfected and control transfected MCF7 cells lines will have a higher 
incidence of metastasis than the wild type  MCF7 cells when supplemented with 
oestradiol but there was no association of rash expression with in vivo 
metastatic capacity of human mammary carcinoma cell line (Gelmann, 
Thompson & Sommers, 1992). 
Thus, applying of screening/prevention strategy and novel treatment planning is 
decreasing breast cancer mortality. However, approximately 120,000 deaths 
due to breast cancer are predicted annually in the US and Europe (Jemal et al., 
2009; La Vecchia et al., 2009). As genomic studies develop, more sub-
classification of breast tumours into new molecular structures is expected to 
take place.  
1.3 Prostate cancer 
The prostate is located in the pelvis, surrounded by the rectum posteriorly and 
the bladder superiorly. It is formed from branching glands, with ducts that are 
padded with secretory epithelial and basal cells. Scattered neuroendocrine cells 
are also present within the tissue and are believed to serve a paracrine function 
for the differentiation of male specific characteristics. Epithelial cells represent 
the major cell type in the gland and are androgen-dependent for growth. The 
epithelium consists of two histologically distinct layers. The secretory luminal 
layer formed from tall columnar cells that produce Prostate Specific Antigen 
(PSA), Prostatic Acid Phosphatase (PAP) and human kallikrein-2 that are 
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secreted as part of seminal fluid. Traditionally, basal and luminal cells were 
considered two distinct cell types; however, differentiating transit amplifying 
cells give rise to heterogeneous subpopulations of cells as they migrate from the 
basal to the luminal layer (Hudson et al., 2001). The basal layer is not androgen 
dependent for growth and is believed to contain epithelial stem cells. 
Surrounding the gland is a stroma that includes fibroblasts, smooth muscle, 
nerves, and lymphatics. Stromal-epithelial interactions remain poorly 
understood, but insights suggest that stroma produces multiple factors 
important for development and growth of a healthy prostate as well as 
potentially contributing to the pathogenesis of prostate cancer Like activated 
stromal cell phenotypes, modified extracellular matrix (ECM) composition, and 
increased microvessel density (Krušlin, Ulamec & Tomas, 2015; Oh et al., 2003). 
Prostate cancer is the most common non-skin cancer in elderly males (> 70 
years of age) in Europe. It is an important health concern, especially in 
developed countries with a greater proportion of elderly men. The incidence is 
highest in Northern and Western Europe (> 200 per 100,000 men), while rates 
in Eastern and Southern Europe are lower but have shown a continuous rise. 
The incidence of prostate cancer has significantly increased in the past two 
decades due to screening, advanced biopsy techniques for diagnosis and 
greater public awareness. Changes in mortality however have not increased 
concordantly and in some countries mortality has decreased. During the last 
twenty years, the 5-year relative survival percentages for PCa steadily 
increased from 73.4% in 1999-2001 to 83.4% in 2005-2007 (Mottet et al., 2016). 
The difference between reported incidence and mortality rates leads to the 
potential conclusion that only a small proportion of low-risk prostate cancers will 
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proceed to life-threatening disease or alternatively new treatments have 
improved prognosis (Damber, 2008).  
One of the major risk factors for prostate cancer, in addition to age and inherited 
susceptibility, is diet. Diets rich in fat and red meat are suggested to be 
associated with increased prostate cancer incidence whereas vitamin E, 
carotenoids, and selenium are protective (DeMarzo et al., 2003). In contrast, a 
comprehensive follow-up of Selenium and Vitamin E Cancer Prevention Trial 
(SELECT) participants showed that healthy men with average risk of prostate 
cancer exposed to contemporary community standards of screening who took a 
common dose and formulation of vitamin E have a significantly increased risk of 
prostate cancer. Thus, it is inconclusive that selenium and Vitamin E are of 
beneficial effect against prostate cancer progression (Klein et al., 2011). 
The formation of carcinogens during cooking such as polycyclic aromatic 
hydrocarbons (PAHs) and heterocyclic amines (HCAs) has been suggested to 
contribute to tumour formation (Chiang & Quek, 2017). Saturated fats may lead 
to increased circulating insulin-like growth factor-1 (IGF-1), which in turn leads 
to PCa progression (Masko, Allott & Freedland, 2013). Most protective dietary 
factors such as vitamin E are potent antioxidants suggesting that oxidative 
stress could promote prostate carcinogenesis. Possible sources of oxidant 
stress are endogenous metabolism and  inflammation (DeMarzo et al., 2003) 
Clinically, prostate cancer is diagnosed as local or advanced and treatments 
vary from monitoring to radical local treatment or androgen-deprivation. 
Androgen-deprivation decreases symptoms in about 70-80% of patients with 
advanced prostate cancer, however, most tumours relapse in two years to an 
incurable androgen-independent state (Amin et al., 2005). 
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Prognosis depends on disease burden at diagnosis (Damber, 2008). In general, 
patients with a high tumour burden do poorly, whereas patients with a low 
tumour burden will do much better, irrespective of treatment regimen. In other 
words currently the disease determines outcomes more than the choice of 
treatment. Stage, grade, and PSA are potent predictors and other markers 
seem to, so far, add little prognostic information (Graefen et al., 2004). Tissue 
markers of prostate needle-biopsy samples have failed to supply useful further 
prognostic information, even though many of the markers provide independent 
prognostic proof on post-prostatectomy specimens (i.e., too late to be of real 
value). Thus there is the need to identify other markers that could improve 
prognostics and outcomes. However, identifying molecular pathways that 
control the development and progression of prostate cancer is a real challenge, 
because of the heterogeneity and multifocality of tumours. The rise of new 
investigative tools such as DNA microarray technology, next generation 
sequencing and the use of proteomics may improve the knowledge concerning 
the initiation, development and progression of prostate cancer. These strategies 
allow detection of nucleotide substitutions, insertions, deletions, copy number 
variations, and chromosomal rearrangements. These have identified biomarkers 
and novel targets for drug developments such as v-erb-b2 avian erythroblastic 
leukaemia viral oncogene homolog 2 (ERBB2/ Her-2/neu) status (Hassan & 
Gomez, 2015). It may also become possible to distinguish between less-
aggressive and aggressive types reserving radical treatment for the latter. 
1.4 Breast and prostate cancer metastatic process 
Tumour cells are capable of invading adjacent and distant tissues to form 
secondary tumours through a process known as metastasis (Hanahan & 
Weinberg, 2000), which is a key characteristic of malignancy (Voulgari & 
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Pintzas, 2009).  Approximately 90% of all cancer-related deaths are associated 
with metastasis (Spano et al., 2012). Most tumours metastasise through the 
bloodstream and this involves a series of cellular adaptations, including invasion 
and migration from the primary tumour; intravasation into the vasculature; arrest 
and extravasation from the vasculature into the distant organ; and proliferation 
and survival in the new tissue microenvironment The acquisition of these 
biological traits by tumour cells involves the coordination of both intrinsic and 
extrinsic signals. 
The first step of metastasis is invasion into the surrounding tissue. Cells must 
undergo modification in their cell-cell and cell-matrix adhesion interactions to 
disassociate themselves from the tumour (Cavallaro & Christofori, 
2004). Acquisition of an invasive phenotype require alterations in expression of 
genes that regulate cell-cell adhesion, as well as proteolytic degradation of the 
extracellular matrix (ECM) (Friedl & Wolf, 2003). The acquisition of this 
phenotype alongside an increase in cell mobility is fundamental to epithelial to 
mesenchymal transition (EMT) (Fig 1.1). Tumour cells undergoing EMT show 
unique phenotypes express higher levels of cell motility proteins and have 
enhanced migratory and invasive potential. This involves changes in cell 
adhesion molecule expression in particular switching of E-cadherin expression 
to N-cadherin expression. During EMT E-cadherin expression is typically 
downregulated whereas N-cadherin expression is up-regulated, referred to as a 
“cadherin switch”. TGF-beta originates from many tissues, but is most abundant 
in bone, kidney, lung, and placental tissue. TGF-beta is synthesied by many but 
not all parenchymal cell types, and is also produced or released by infiltrating 
cells such as lymphocytes, monocytes/macrophages, and platelets (Branton & 
Kopp, 1999). E/N-cadherin switch promotes cancer progression via TGF-β-
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induced EMT in extrahepatic cholangiocarcinoma. During EMT, epithelial cells 
are transformed into mesenchymal cells changing their morphology from a 
cobblestone-like monolayer with apical-basal polarity to flat and spindle-shaped 
mesenchymal cells to gain the ability to move (Lee, Hwang & Choi, 2016). 
Cells undergoing EMT develop interactions with the extracellular environment in 
localized areas of the carcinoma, where they lose intercellular coherence, 
modify extracellular matrix (ECM) and cytoskeletal structure to enable invasion 
into the extracellular space (Yang & Weinberg, 2008). EMT is associated with 
the expression of extracellular matrix proteases, such as urokinase-type 
plasminogen activator (uPA) and matrix metalloproteases (MMPs) Such as 
MMP-2, MMP-13 and MMP-12 in breast cancer and MMP-2 in prostate cancer , 
which degrade the ECM linked to the plasma membrane and localized to 
invadopodia during metastasis (Friedl & Wolf, 2003; Gilles et al., 2005; Son & 
Moon, 2010). EMT is a reversible and an inverse process, called mesenchymal-
epithelial transition (MET) can occur at metastatic sties. Cells undergoing MET 
show increase cell-cell adhesion and gain back an epithelial phenotype (Davies, 
1996; Foroni et al., 2012). 
It is well known that tumour expansion requires a combination of increased 
proliferation and decreased apoptosis. One of the most well-studied regulators 
of cellular proliferation and apoptosis is TGFβ, which can inhibit cell cycle 
progression in non-malignant cells and early malignant tumour cells, but can 
also stimulate proliferation through poorly understood processes in more 
progressed cancer cells; TGFβ can also inhibit apoptosis in a variety of cell 
types (Massagué, 2012). TGF-β is a multifunctional cytokine, which triggers 
diverse cellular processes including growth arrest, tissue fibrosis, and EMT. To 
activate SMAD and MAPK signalling pathways TGF-β binds to TGF-β type II 
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(TβRII) and type I (TβRI) serine/threonine kinase receptors, respectively. 
Recent studies have shown a crucial role for TGF- β signalling pathways that 
induce EMT through Smad-dependent by phosphorylation of the cytoplasmic 
signaling molecules Smad2 and Smad3 and Smad-independent pathways 
(Meulmeester & Ten Dijke, 2011; Son & Moon, 2010). Transcriptional activities 
of Snail, ZEB and basic helix-loop-helix (bHLH) families which are important 
factors as inducers of epithelial–mesenchymal transition (EMT) and potent 
repressors of E-cadherin expression regulated by TGF-β to activate 
mesenchymal markers and degrade epithelial markers in a Smad-dependent 
fashion(Nantajit, Lin & Li, 2015; Peinado, Olmeda & Cano, 2007a), leading to 
changes in cytoskeleton organization, cell survival, migration and invasion. 
These effects are mediated through a range of zinc finger transcription factors 
including snail, twist and ZEB family members, which directly bind the E-box of 
the E-cadherin promoter to suppress E-cadherin expression. Furthermore, high 
level N-cadherin expression is often associated with poor prognosis. N-cadherin 
is also expressed in endothelial cells and plays an important role in the 
maturation and maintenance of normal vessels and tumour-associated 
angiogenic vessels (Batlle et al., 2000; Mariotti et al., 2007). 
Cadherins are important mediators of EMT. They are type 1 membrane 
glycoproteins and function as active membrane-spanning macromolecular 
complexes. The extracellular regions are responsible for adhesive recognition, 
binding to the ectodomains of other cadherins presented on neighbouring cells. 
Cadherin cytoplasmic elements  interact with proteins that connect the cadherin 
receptor to key intracellular processes including the actin cytoskeleton, cell 
signalling and trafficking (Jeanes, Gottardi & Yap, 2008). Cell-cell adhesions are 
mediated primarily by cadherins expressed at adherent junctions.  E-cadherin, 
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as a typical molecule in epithelial adherent junctions, has been found to 
inactivate and repress tumour progression by maintaining intact cell-cell 
interactions and inhibiting cell mobility, invasion and metastasis (Perl et al., 
1998; Thiery & Sleeman, 2006). Decreased E-cadherin expression is usually 
observed in aggressive cancers within epigenetic silencing, proteolytic cleavage, 
proteosomal degradation or mutation (Niederhuber et al., 2013). This helps to 
initiate the progression of invasive carcinoma by promoting subsequent aspects 
of EMT, as the loss of many epithelial markers including E-cadherin, occludin, 
claudins and β-catenin. This induces the expression of mesenchymal markers 
including N-cadherin, Snail, vimentin, R-cadherin and cadherin-11 and 
acquisition of mesenchymal phenotype, such as invasion and cell motility 
(Bailey, Singh & Hollingsworth, 2007; Zeisberg & Neilson, 2009). As a 
consequence, primary cancer cells lose cell-cell adhesion through E-cadherin 
repression, break through the basement membrane and enter the bloodstream 
through intravasation. Later, the circulating tumour cells exit the bloodstream to 
migrate to specific metastatic sites where they undergo mesenchymal to 
epithelial transition (MET) for clonal outgrowth. Factors directly secreted by 
osteoblast or released from the bone matrix during resorption are potential 
chemoattractive agents for bone colonizing breast and melanoma tumours. 
Collagen I as a chemoattractant for human breast cancer cells (MB-MDA-231) 
demonstrated that tumour cells can secret enzymes to release collagen I from 
bone, because the bone matrix is generally composed of type I collagen, which 
is enzymatically degraded during the process of bone resorption and tumour 
infiltration, these collagen fragments could play a biological role in bone directed 
metastasis in vivo. Many cytokines normally present in bone were evaluated as 
possible chemotactic agents for human prostate tumours, including nterleukin-1 
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alpha, interleukin-2, interleukin-6, tumour necrosis factor-beta, transforming 
growth factor-beta, interferon alpha 2-a, EGF and granulocyte macrophage 
colony-stimulating factor (Chaffer & Weinberg, 2011; Cooper & Pienta, 2000). 
E-cadherin influence tumourigenesis by modulation of mitogenic signalling. This 
notion first suggested by observations that cadherin adhesion could promote 
cell proliferation in the PC9 lung carcinoma cell line (Jeanes, Gottardi & Yap, 
2008). Although these cells possess E-cadherin and β-catenin, they adhere 
poorly to one another due to lack of α-catenin. Restoration of α-catenin supports 
cell–cell cohesion and hinders proliferation, suggesting E-cadherin adhesion 
might associate in contact inhibition of growth. Growth factor stimulation is a 
major driver of proliferation and is often upregulated in tumours. Notably, many 
epithelial cancers display high levels of epidermal growth factor receptor (EGF-
R, ErbB1), which is implicated in cell proliferation, invasion and metastasis 
(Bublil & Yarden, 2007). Support for this idea comes from the following lines of 
evidence. First, E-cadherin co-accumulates with EGF-R at cell–cell contacts and 
can physically interact with the EGF receptor and also with other members of 
the ErbB receptor tyrosine kinase family. EGF-R did not, however, interact with 
N-cadherin, suggesting a degree of selectivity among the classical cadherins. 
Second, E-cadherin can inhibit cell responsiveness to EGF stimulation. This 
was first suggested by (Qian et al., 2004) who observed that mitogenic 
responsiveness to EGF (measured cell proliferation and activation of Ras 
signalling) decreased as cells grew to confluence. In addition, activation of the 
Src family of kinases or of the Ras/MAPK pathway can, however, be initiated by 
a kinase-impaired EGFR and is linked to survival.(Jeanes, Gottardi & Yap, 2008; 
Walker et al., 1998)  
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N-cadherin overexpression has been observed in several carcinomas. 
Expression of N-cadherin is related to metastasis in prostate cancer and 
increases metastases in patients with castration-resistant tumours (Zhuo et al., 
2013). N-cadherin expression is regulated by a wide range of factors leading to 
changes in cell-cell adhesion, differentiation, embryogenesis, migration, 
invasion and signal transduction. The aberrant expression of N-cadherin 
attributes a more fibroblastic phenotype to cancer cells, and they become more 
motile and invasive. One of the transcription factors responsible for upregulation 
is twist (Derycke & Bracke, 2004). The up-regulation of N-cadherin in 
aggressive carcinomas is crucial for invasion. Studies have shown that N-
cadherin mediates transendothelial migration of cancer cells an essential step in 
metastasis (Drake et al., 2009; Qi et al., 2005) and N-cadherin aimed 
therapeutic strategies minimize N-cadherin positive tumour growth and 
metastasis (Shih & Yamada, 2012).  
Kim et. al. (2012) explained that N-cadherin expression appears to be more 
critical for tumour malignancy than E-cadherin. N-cadherin promotes cell motility 
and invasion via interactions with growth factor receptors such as FGF 
receptors and PDGF receptor. N-cadherin further promotes cell growth and 
survival by suppressing apoptotic signals and numerous clinical studies have 
shown that aggressive human tumours express N-cadherin in situ, indicating a 
critical role for cadherin switch in human tumourigenesis. Therefore, both EMT 
and resistance to apoptosis in the absence of attachment to extracellular matrix 
(ECM) or upon cell adhesion to inappropriate location are important processes 
for metastasis and they share common regulators, such as Twist, Snail, Zeb1, 
E-cadherin, and N-cadherin (Kim et al., 2012; Paoli, Giannoni & Chiarugi, 2013).  
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Transcriptional regulation of E-cadherin differs in cultured cells versus 
xenografts, which more realistically reflect E-cadherin regulation in cancers in 
humans. Moreover, the aggressive nature of xenografts positive for E-cadherin 
and the frequency of metastases positive for E-cadherin suggest that high E-
cadherin expression in metastatic prostate cancer is associated with aggressive 
tumour growth (Putzke et al., 2011). Genetic susceptibility factors may influence 
loss of E-cadherin expression in breast cancer, might provide new insights on 
pathways of E-cadherin loss against obtaining N-cadherin expression consistent 
with histology analysis (Horne et al., 2018). 
  
15 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.1 Schematic representation of EMT and anoikis resistance. 
EMT-inducing factors, such as TGF-β and FGF activate transcriptional 
factor, Twist, Snail and Zeb1. Activated these transcriptional factors 
repress E-cadherin (encoded CDH1 gene) expression and induce N-
cadherin expression (Cadherin switch). Cadherin switch induces EMT 
and anoikis resistance, which are associated with tumour metastasis 
(Kim et al., 2012). 
 
 
1.5 Transcriptional regulators of EMT: Snail, slug, ZEB1, ZEB2 and Twist  
Snail family members are the most studied effectors of EMT. These include 
scratch (SNAIL1), Slug (SNAIL2) and the less characterized SMUC (SNAIL3) 
(Nieto, 2002). All are zinc-finger type transcription factors and share a highly 
conserved C-terminal domain, containing four to six C2H2 type zinc fingers and 
bind to the E-box 5′-CACCTG-3′(Nieto, 2002). They have differential binding to 
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E box with snail having the greatest affinity (Bolós et al., 2003). Snail inhibits 
expression of epithelium-specific genes such as PTEN, Muc1, claudin, and 
occludin as well as some nuclear factor receptors (Vitamin D receptor, HNF-1α) 
(Peinado, Olmeda & Cano, 2007b). PTEN as an important tumour suppressor 
for many types of cancer and can inhibit cellular proliferation, survival and 
growth by inactivating PI 3-kinase-dependent signalling (Leslie & Downes, 
2004). 
TGFβ and Wnt family proteins and growth factors that work through Receptor 
Tyrosine Kinases (RTKs), all promote SNAIL1 expression. SNAIL1 and SNAIL2 
co-operate with other transcription regulators to control gene expression. For 
example, SNAIL1 co-operates with ETS1, which is activated by MAPK, to 
activate MMP expression. Matrix metalloproteinase-3 (MMP3) can stimulate 
EMT of cultured mouse mammary epithelial cells through a process that 
involves increased expression of Rac1b, a protein that stimulates alterations in 
cytoskeletal structure and cause cells to spread and cover large surfaces. Thus, 
MMP-3 causes EMT associated with malignant transformation through a 
pathway dependent upon production of reactive oxygen species (ROS). Snail, a 
ROS-dependent mediator of MMP-3-induced changes, is regulated by NF-kB in 
response to MMP-3. Furthermore, MMP-3 gives rise to binding of p65 and cRel 
NF-kB subunits to the Snail promoter, leading to its transcription. It also co-
operates with the SMAD3–SMAD4 complex to cause TGFβ-mediated repression 
of E-cadherin and occludin expression (Gao et al., 2016; Nelson et al., 2008). 
Many studies have described the presence and role of MMPs in many types of 
cancers including breast cancer such as MMPs (MMP-2, -7, -9, -10, -11, -13, -
14 and -15) have been involved in BC progression and metastasis. Specifically 
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MMP-1, -2, -3, -7, -9 and -14 are implicated as key factors in tumour invasion, 
metastasis and angiogenesis (Merdad et al., 2014). 
The ZEB family of transcription factors consists of two members: ZEB1(TCF8 
and δ EF1) and ZEB2 (ZFXH1B and SIP1) (Vandewalle, Van Roy & Berx, 2009). 
The family’s structure is characterised by the presence of two zinc finger 
domains and a homeodomain. The zinc finger domains are located at both ends 
of the protein and contain three to four zinc fingers of the C2H2 and C3H type. 
The homeodomain is found in the middle part of the protein. ZEB proteins 
interact with DNA through the simultaneous binding of the two zinc finger 
domains to E-boxes (Vandewalle, Van Roy & Berx, 2009). Both are potent 
repressors of E-cadherin, but the relative impact of ZEB and Snail members in 
EMT is contested. Some studies suggesting that Snail may be more influential 
(Vega et al., 2004), whereas other studies found that silencing of ZEB1 has a 
greater impact on E-cadherin expression than Snail (Eger et al., 2005; 
Vandewalle et al., 2005; Vandewalle, Van Roy & Berx, 2009). 
TWIST, a highly conserved basic helix–loop–helix transcriptional factor is 
transcriptionally controlled by EGFR/ STAT3 and NF-kB signalling. In cancer 
cells, TWIST1 represses E-cadherin and induces N-cadherin expression 
independent of SNAIL and probably by the association with other proteins. 
TWIST recruits the methyltransferase SET8, which interferes H4K20 
monomethylation, a histone mark that is associated with suppression at E-
cadherin promoters and with activation at N-cadherin promoters. Studies also 
showed that ectopic expression of TWIST results in both morphological and 
molecular modifications in the expression of particular proteins through 
downregulation of epithelial markers and upregulation of mesenchymal markers 
(Gao et al., 2016). 
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1.6 Matrix metalloproteinases (MMPs) 
Matrix metalloproteinases (MMPs) are proteolytic enzymes responsible for the 
hydrolysis of basic elements of the extracellular matrix (ECM) to facilitate 
tumour cell dissemination. MMPs have a multi-domain structure which includes 
a signal peptide domain, a pro-peptide domain and a catalytic domain (Gong, 
Chippada-Venkata & Oh, 2014).  Evidence suggests that MMPs participate in 
several stages of cancer progression modifying six principal processes of cell 
physiology, including self-supporting growth signals, resistance to growth 
inhibitory signals, insensitivity to apoptosis, over replication, angiogenesis, and 
invasion to other tissues and metastasis (Egeblad & Werb, 2002; Hanahan & 
Weinberg, 2000). Furthermore, MMPs can directly facilitate cancer progression 
by degrading the basement membrane, allowing cancer cells to invade into the 
surrounding stroma (Fig 1.2), but MMPs can also act directly on the tumour cells, 
releasing factors that promote growth or suppress apoptosis (Gialeli, Theocharis 
& Karamanos, 2011). Imbalances in MMPs activate cellular processes that 
cause DNA damage and stimulate genomic instability(Radisky & Bissell, 2006) 
Furthermore, MMPs have been implicated in tumour angiogenesis, the 
penetration of a tumour by new vessels sprouting from existing ones 
(Kessenbrock, Plaks & Werb, 2010; Weis & Cheresh, 2011). MMPs can also 
affect the tumour microenvironment by promoting the development of activated 
stromal cells. Fibrosis, the abundance deposition of collagen and fibroblast 
proliferation that is correlated with most types of cancer, is largely the product of 
myofibroblasts. These cells accumulate by activation of stromal fibroblasts or 
circulating fibrocytes, or directly from epithelial cells by EMT (Mehner & Radisky, 
2013). Myofibroblasts are significant origins of breast cancer MMPs  (Del Casar 
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et al., 2009; Heppner et al., 1996; Vizoso et al., 2007) and tumour progression 
and poor prognosis is associated with stromal expression of MMP-1, MMP-7, 
and MMP-12 (Finak et al., 2008) and with fibroblast-specific production of MMP-
9, MMP-11, and MMP-14 (Del Casar et al., 2009; Vizoso et al., 2007). Cancer 
cells can also directly secrete variant isoforms of collagen that are resistant to 
cleavage by MMPs and that can function as tracks for guiding cancer cell 
invasion in MMP-rich microenvironments (Han et al., 2010; Makareeva et al., 
2010).  
 
 
 
 
Figure 1.2  MMPs facilitate EMT-associated tumour progression.               
A. Exposure of epithelial cells to MMPs can directly induce EMT. B. 
Increased expression of MMPs in cells which have undergone EMT 
facilitates cancer cell invasion.  C. EMT can produce non-malignant 
stromal cells which drive tumour  initiation and progression through 
production of MMPs (Radisky & Radisky, 2010). 
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In prostate cancer tissue, there is an imbalanced expression of MMPs and 
tissue inhibitor of metalloproteinase (TIMP), displayed as a general loss of 
TIMP-1 and upregulation of MMPs. As a result, it is generally understood that 
MMPs are more effective in advanced stages of prostate cancer, as shown by 
the fact that most MMPs display higher expression in cancers with high Gleason 
scores.  Analysis of MMP mRNA and protein levels in the serum and tissue 
specimens from prostate cancer patients revealed that increased expression of 
MMP-2, -3, -7, -9, -13, -14, -15 and -26 is associated with advanced or 
metastatic disease, while MMP-1 expression is associated with lower grade 
tumours and incidence of invasion. The distinct roles these MMPs play in the 
hallmarks of cancer progression are illustrated in (Fig 1.3). Among the various 
members of the homologous MMP family, MMP-2, -7, -9 and MT1-MMP are the 
best investigated for their roles in prostate cancer progression. Overall, 
expression of these MMPs promote prostate cancer progression but with 
differences in their mode of expression, role and prognostic importance. For 
instance, in genetically-engineered mice, although the reduction of MMP-2, -7, 
or -9 in CR2-Tag mice all led to decreased tumour vascularity, the loss of MMP-
2 decreased lung metastasis and improved survival, whereas the lack of MMP-9 
led to increased perivascular invasion (Littlepage et al., 2010). As described 
previously by (Merdad et al., 2014) MMPs play an important role in breast 
cancer progression , metastasis, invasion and angiogenesis and warrant further 
study as diagnostic markers and potential drug targets (Fig 1.4) 
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Figure 1.3   Roles of MMPs in several hallmarks of prostate 
cancer progression (Gong, Chippada-Venkata & Oh, 2014) 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.4 Role of MMPs in breast cancer progression   
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1.7 Preferential metastasis of prostate and breast cancer to bone 
In 1889, Stephen Paget classically described the “seed and soil” hypothesis as 
the propensity of circulating tumour cells (CTCs) to home to specific organs, 
irrespective of the nearest anatomical location to the primary tumour (Paget, 
1989). The diffusion of prostate and breast cancer metastatic cells particularly to 
the skeleton is defined as osteotropism and is defined by many markers 
expressed by the tumour cells and the bone microenvironment such as stromal 
cells. The interactions between cancer cells and the endothelium of the bone 
marrow vasculature are one of the core processes supporting extravasation 
from blood vessels and is proposed to underlie bone-specific dissemination (Fig 
1.5). During this process, surface molecules expressed on cancer cells such as 
the chemokine (C-X-C motif) receptor CXCR4 which broadly expressed by both 
mononuclear cells and progenitor cells in the bone marrow, CCL2, αvβ3 integrin, 
CD44 and RANK are directly engaged in homing to the bone. The connection 
between CXCR4 and its ligand CXCL12 also known as stromal derived factor 1 
(SFD1), expressed at high levels in tissues invaded by metastasis, is very 
important in prostate and breast cancer preferential metastasis to the skeleton 
(Zoni & van der Pluijm, 2016). CXCL-12 is produced in large amounts by bone 
marrow. Metastatic cells from breast or prostate cancers that express CXCR-4, 
the CXCL-12 receptor, migrate preferentially to the marrow due to the 
chemotactic properties of CXCL-12. RANKL and RANK are required for the 
development of the lactating mammary gland during pregnancy, and for lymph 
node organogenesis in mouse embryos (Jones et al., 2006). RANK 
overexpression in human breast cancer cells increases their aggressiveness 
buy increasing the osteoclastongesis process that increase osteoclast 
degradation of bone and may result in poorer clinical outcome (Santini et al., 
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2011). RANKL can be released as a soluble factor by the proteolytic effects of 
matrix metalloproteases (MMP-7, MMP-13) and membrane metalloproteases 
(MMP-1), which are produced during the formation of bone metastases. In vitro, 
soluble RANKL promotes the migration of tumour cells that express RANK. 
Thus, RANKL may share with chemokines the ability to help tumour cells to 
metastasise to the bone marrow (Clézardin, 2017). Data suggests that RANK 
expression status influences whether tumours predominantly migrate into bone. 
The association of high RANK expression with osteotropism in murine models 
was confirmed across diverse tumour cell types, including breast cancer and 
melanoma (Jones et al., 2006). RANK overexpression in human breast cancer 
cells increases their aggressiveness and may result in a poorer clinical outcome. 
In fact, RANK expression progressively increases with pathologic grade and 
significantly correlates with a high proliferative index in clinical samples of 
breast cancer patients. Higher levels of RANK mRNA expression were found in 
(ER- PR-) tumours, which were consistent with the higher degree of RANK 
protein expression in these tumours. ER- PR- tumours are more aggressive, 
show a higher incidence of metastasis and worse prognosis than luminal 
tumours, and contain a higher frequency of CD44+/CD24- stem cell markers. 
Moreover, RANK/RANKL mRNA expression levels allow discrimination between 
metastatic and non-metastatic adenocarcinomas (Palafox et al., 2012). 
 
 
. 
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Figure 1.5: Multiple origins of tumour-induced neovascularisation. Showing the relation 
between tumour cells and  the formation of new blood vessel  (Weis & Cheresh, 2011) 
 
1.8  Vicious cycle in bone microenvironment 
 
The “Vicious Cycle” hypothesis provided the basis for the inhibition of bone 
resorption as a strategy to interfere with bone metastatic tumor growth.  
However, in the clinical setting inhibition of bone resorption while an effective 
strategy to reduce skeletal-related events may have little direct negative impact 
on cancer cell growth and tumour mass. This observation suggests that other 
mechanisms than bone resorption support cancer cell growth at the bone 
metastatic site (Hensel & Thalmann, 2016). 
Bone is composed of hard-mineralized tissue; therefore it is highly resistant to 
invasion and destruction by cancer cells opposed to other metastatic sites. 
Osteoclasts have been described as the most efficient cells to induce bone 
resorption ‘‘bone-resorbing machines’’. Consequently, to grow within the bone 
matrix, the cancer cells must control the capacity to induce osteoclastic or 
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osteoblastic activation, which is the main cellular mechanism for cancer-induced 
bone destruction. Elevated osteoclastic bone resorption would then provide a 
microenvironment in which cancer cells can grow and induce further molecular 
interactions with the different cytokines within the bone microenvironment (Azim, 
Kamal & Azim, 2012). TGF-β which is deposited in the bone matrix by 
osteoblasts and released and activated by osteoclast during osteoclastic bone 
degradation. TGF-β is not the most abundant growth factor in bone, but it plays 
the most important role in the progression of osteolytic metastases (Buijs, 
Stayrook & Guise, 2011; Fox & Lovibond, 2005) .  
It has been suggested that cancer cells produce soluble factors that activate 
directly (RANKL) or indirectly via osteoblasts parathyroid hormone-related 
peptide (PTHrP), IL-8, osteoclast differentiation and maturation. During bone 
degradation, osteoclasts release tumour supportive growth factors stored in the 
mineralized bone matrix (insulin-like growth factor-1, fibroblast growth factor, 
TGF- β, etc.). This vicious cycle has been proposed to accelerate tumour 
development in bone. RANKL/RANK blocking by soluble RANK (sRANK) or 
OPG released by osteoblasts (OBs) successfully prevented the development of 
bone metastases (Ando et al., 2008). 
Tumour cells release several factors that stimulate osteoclast activity and bone 
resorption. Among them, parathyroid hormone-related peptide (PTHrP) was the 
first to be identified as involved in malignant osteolysis. PTHrP shares structural 
homology with parathyroid hormone and can, therefore, bind to its receptor 
PTH-1R, thus, stimulating the expression of RANKL, which in turn indirectly 
leads to the formation of new osteoclasts and increased bone resorption. PTHrP 
can also act in an autocrine form by promoting the production of connective 
tissue growth factor (CTGF). Connective tissue growth factor (CTGF)  belongs 
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to the CCN family of cysteine-rich proteins and stimulates osteoclast formation 
in vitro. In vivo, the treatment of animals with an antibody to CTGF prevents the 
formation of osteolytic metastases induced by MDA-MB-231 cells (Clézardin, 
2017). 
1.9 Bone morphogenetic proteins (BMPs) 
Members of the transforming growth factor (TGF) superfamily, which include 
bone morphogenetic proteins (BMP), are involved in the control of various 
biological processes, including differentiation, proliferation, apoptosis, and 
regulation of invasiveness (Buijs et al., 2007a). BMP-7 protein is expressed at 
higher levels in PCa bone and soft tissue metastasis when compared with 
primary PCa, supporting that BMP-7 signaling is related to clinical disease 
progression (Morrissey et al., 2010). Bone morphogenetic protein-6 (BMP-6) 
has been strongly involved in prostate cancer development and bone 
metastasis (Darby et al., 2008). Other BMPs may play a protective role against 
cancer progression such as BMP-9, that can inhibit cell growth, adhesion, 
invasion, and migration of prostate cancer cells in vitro (Ye, Kynaston & Jiang, 
2008). In breast tumours, BMP-2, BMP-4, BMP-5 and BMP-7 expression has 
been described as elevated and the latter two associated with poor prognosis. 
The importance may be that BMPs have two way actions in breast cancer, such 
as BMP-4, which not only suppresses breast cancer cell growth, but also 
encourages invasion and migration. Studies related to BMP-4 expression with 
low proliferation tumours, but also increased recurrence (Zabkiewicz et al., 
2017). 
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Runt-related transcription factor 2 (Runx2) and Osterix (Osx) are downstream 
targets of BMP during osteogenesis. Runx2 is expressed in chondrocyte and 
osteoblast and it plays many roles in the process of chondrogenesis and 
osteogenesis (Baek, Choi & Kim, 2014). It functions as a regulator of osteoblast 
differentiation at an early stage and plays a role in skeletal morphogenesis and 
tooth development. Further, it is known to regulate G1 transition in osteoblast 
cells (Vimalraj et al., 2015). 
In normal prostate tissues, Runx2 is expressed but its physiological role is 
unknown, both Runx1 and Runx2 have been shown to regulate prostate specific 
antigen (PSA) through the presence of Runx2 binding sites in the regulatory 
region of the gene. Many studies indicate a higher level of Runx2 expression in 
prostate cancer and some shown that Runx2 is associated with disease 
progression (Chua et al., 2009; Lim et al., 2010). Other studies support a role for 
Runx2 in driving a more aggressive phenotype in prostate cancer. Hypoxic 
selection of LNCaP cells led to the outgrowth of an androgen independent 
subline that showed increased survival, invasiveness and tendency to 
metastasise in vivo. These changes were associated with up-regulation of 
Runx2 that was at least in part responsible for the more aggressive phenotype 
(Blyth et al., 2010). 
1.10 Phytoestrogens as a potential treatment 
The search for plant-derived anti-cancer agents started in the 1950s with the 
discovery and development of the vinca alkaloids, vinblastine and vincristine, 
and the isolation of the cytotoxic podophyllotoxins. The United States National 
Cancer Institute (NCI) launched a comprehensive plant collection program in 
1960, concentrated mainly in temperate regions. This led to the discovery of 
various novel chemotypes displaying a range of cytotoxic activities, including 
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the taxanes and camptothecins, but their development into clinically active 
factors spanned a period of some 30 years, from the early 1960s to the 1990s. 
This plant collection program was ended in 1982, but the development of new 
screening technologies led to the revival of collections of plants and other 
organisms in 1986, with a focus on the tropical and sub-tropical regions of the 
world (Cragg & Newman, 2005). 
In postmenopausal women, consumption of isoflavones was found to be 
associated with reduction of breast cancer incidence, mammary gland density 
and proliferation ability of mammary gland cells. These effects have been 
associated with the ability of isoflavones to increase serum Sex Hormone-
Binding Globulin (SHBG) concentration, thereby reducing the bioavailability of 
sexual hormones in hormone-dependent tissues. Moreover, in peripheral 
tissues, isoflavones inhibit enzymes involved in the processes of cell 
proliferation (e.g. tyrosine kinases such as AKT and mitogen-activated protein) 
and reduce estradiol availability through the inhibitory effect on aromatase P450.  
(Lee, Lee & Sohn, 2005; Pilsakova, Riecanský & Jagla, 2010) 
Hormone replacement therapy (HRT) after breast cancer raises many problems 
due to the oestrogen dependence of breast cancer, while the possible increased 
risk of breast cancer in healthy women taking HRT has to be considered for the 
treatment of oestrogen deprivation. Most physicians continue to avoid HRT in 
breast cancer survivors because of concerns regarding the enhancement of 
growth and dissemination of malignant cells while on HRT. Besides these (HRT) 
drugs, which are prescribed under medical control, soy phytoestrogens derived 
from plants are being promoted as the “natural alternative” to HRT, and have 
been available without restriction as nutritional supplements for many years. 
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After breast cancer, many women decide, sometimes ’by themselves’, to have 
these phytoestrogens to mitigate menopausal symptoms (This et al., 2001).  
Phytochemicals are chemical compounds found naturally in plants and consist 
of about 4000 different chemicals. A broad range of plant-derived compounds 
have been reported to have chemopreventive effects. Phytoestrogens are 
classified into four main groups: isoflavones (genistein, daidzein, glycetin and 
kaempferol), lignans (secoisolariciresinol, matairesinol, pinoresinol, lariciresinol), 
coumestan (coumestrol) and stilbenes (resveratrol). Western societies have 
been known to intake more foods containing lignans, while Asian populations 
eat more soy foods containing isoflavones (Lee, Hwang & Choi, 2016). 
Concentrations of phytoestrogens and their metabolites in plasma and urine 
have been recorded in several studies of humans and animals. In healthy 
people consuming diets without soy, plasma concentrations of isoflavones are 
usually in the nanomolar range (e.g., < 40 nmol/L). In contrast, plasma 
isoflavones concentrations increase considerably in the micromolar range after 
ingestion of isoflavones from soybean milk, soy meal, or baked soybean powder 
(Bhathena & Velasquez, 2002). 
Paraskevi Moutsatsou, (2007) define phytoestrogens as a large family of plant-
derived compounds having significant oestrogen agonist/antagonist activity. 
These, naturally occurring molecules, include the isoflavonoids, lignans, 
coumestans, stilbenes and the flavonoids quercetin and kaempferol . Their 
effects, work via the oestrogen receptor subtypes ERα and ERβ, one cell 
type/tissue specific and dose-dependent. Phytoestrogens may act as “natural” 
selective oestrogen modulators (SERMs) and may possibly be considered for 
the prevention of postmenopausal osteoporosis and cardiovascular disease 
without an adverse effect on breast and uterus. On the other hand, oestrogens 
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are steroid hormones with a complex mode of action, characterised by high 
tissue specificity and dose-dependent activity. They have pleiotropic effects on 
a diverse range of tissues, such as ovary, testis, prostate, breast, uterus, bone, 
liver, cardiovascular, central nervous system and immune system. Effects 
include decreasing nitric oxide production by genistein in cultured mice 
macrophage suggesting a modulation of immune responses and inhibition of 
cultured T cells in response to CD28 monoclonal antibodies. Also, inhibition of 
leukotriene B4, interleukins and its receptors. Genistein, at high concentrations, 
also inhibits cytotoxic T-cell mediated tumoricidal activity and activation of NK 
cells. Oestrogens promote breast and endometrial cancer in women and 
exacerbate autoimmune diseases, whereas the loss of oestrogens during 
menopause has been correlated with osteoporosis, coronary heart disease, 
depression and neurodegeneration. Compounds which inhibit the oestrogenic 
effects (antagonists) in some tissues, such as breast and uterus, while 
enhancing the oestrogens effects (agonists) in other tissues, such as bone, 
brain and cardiovascular cells, are known as selective oestrogen receptor 
modulators (SERMs) (Cooke, Selvaraj & Yellayi, 2006; Moutsatsou, 2007). 
Many epidemiological studies indicate that diets rich in phytoestrogens (PE), 
particularly soy and unrefined grain products, may be associated with low risk of 
some cancers, especially steroid hormone-dependent, e.g. breast and prostate 
cancers (Wietrzyk, Grynkiewicz & Opolski, 2005). Phytoestrogens have an 
oestrogenic activity or are converted to oestrogenic compounds by bacteria in 
the gut. The first class of phytoestrogens is the isoflavonoids, which are present 
in soybean products, some fruits and vegetables, and red clover. Genistein, 
daidzein and glycitein are the main dietary-derived isoflavones.  Most of these 
compounds have a strong affinity for one ER subtype (Pearce & Jordan, 2004).  
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Since the first endocrine agent tamoxifen was described in 1986, tamoxifen as 
the standard endocrine therapy has been shown to reduce ER-positive breast 
cancer. However, more new investigations are suggesting the positive roles of 
naturally occurring selective oestrogen-receptors modulators (SERM) such as 
phytoestrogens as an alternative therapeutic option to avoid increased risks of 
tamoxifen for its detrimental tissue specific results such as thromboembolic 
events, strokes. Also, tamoxifen has shown estrogenic activity in the uterus and 
therefore may increase the risk of endometrial cancer. For example, Targeting 
ERβ and PR by Larrea nitida extracts (LNE) may work as a potential suppressor 
of women’s cancer that enhances differentiation and inhibits ERα-mediated 
proliferation. Data from the studies of naturally-occurring (SERM), both in cell 
culture and in animals have provided more details into a new dimension of the 
complex nature of ER action in health and disease. Furthermore, Larrea nitida 
extracts (LNE) had a selective binding affinity to hERβ rather than hERα and 
treatment of LNE reduced the cell proliferation in the presence of endogenous 
oestrogen (Ahn et al., 2014; Ososki & Kennelly, 2003a). Further to ER-mediated 
signalling mechanisms, there is rising experimental evidence that soy 
isoflavones play important ER-independent effects. Genistein has been shown 
to inhibit the growth of ER-negative breast cancer cells, indicating that other 
cellular mechanisms may play an important role in chemoprevention as well. 
Numerous in vitro studies have revealed that isoflavones inhibit cell proliferation 
and trigger apoptosis by inhibiting the activity of several enzymes, such as 
tyrosine protein kinase, mitogen-activated protein kinase or DNA topoisomerase 
II. additionally, isoflavones, especially genistein, promote antioxidant defence 
and DNA repair, inhibit the development of tumour angiogenesis and metastasis 
and also interfere in other ER-independent signal transduction pathways 
(Uifălean et al., 2015). 
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Over recent years, as indicated by This et al. 2001 many in-vitro studies have 
identified beneficial effects of the main phytoestrogens, especially genistein and 
daidzein. Study of the effect of genistein in cultures of MCF7 cells that express 
the oestrogen receptor alpha (ERα) shows dual effects on mammary cells. 
According to the concentrations of genistein, with high soy dose it increases 
cellular proliferation and cells division, which is dependent on oestrogen 
receptor. While genistein’s effect with oestradiol, the normal oestrogen, acts as 
a competitive inhibitor for the binding site of oestradiol to oestrogen receptor 
and inhibits cell proliferation since it has a lower activity than oestradiol. While 
high doses of genistein (>10 µM/L) inhibit cells proliferation, and this effect is not 
ER-dependent and may related to the inhibition of the tyrosine kinase activity of 
growth factor receptors such as the blocking of AKT signaling cause growth 
arrest and apoptosis (Chandarlapaty et al., 2011; This et al., 2001) 
Genistein is the most abundant isoflavone in soybean products and is well 
known to have various biological activities. Among these, its anti-cancer effects 
against some cancers including breast and prostate carcinomas have been 
considered to be most remarkable. Genistein effectively suppressed BG-1 
ovarian cancer cell proliferation promoted by bisphenol A (BPA) or 17β-estradiol 
(E2). This anti-proliferative effect of genistein was accomplished by reversing 
the effects of E2 or BPA on the expression of cell cycle-related genes. Unlike 
the actions of E2 or BPA, genistein suppressed the expression of cyclin D1 
which with Cdk4 (cyclin dependent kinase 4) plays an essential role in G1 phase. 
It can phosphorylate Rb family proteins to disable their role as transcriptional 
suppressors and allow activation of E2Fgenes - dependent transcription to 
promote S phase entry and initiation of DNA synthesis and promoted the 
expression of p21, which also known as cyclin-dependent kinase inhibitor 
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1 or CDK-interacting protein 1, is a cyclin-dependent kinase inhibitor (CKI), that 
is capable of inhibiting all cyclin/CDK complexes when delivered with E2 or BPA, 
thus, leading to cell cycle arrest in G1 phase (Du, Tong & Ye, 2013; Hwang et 
al., 2013; Xiong et al., 1993). 
Zhao and Mu (2010) indicated that intracellular mechanisms of phytoestrogen 
protection against cellular proliferation of breast cancers might be through: (i) 
binding to nuclear ER and inhibiting genomic ER-mediated gene expression, (ii) 
interaction with membrane-ER, blocking protein kinases and suppressing 
transcription factors, (iii) inhibiting growth factor receptor(GFR) activation and its 
downstream signaling networks, (iv) activating caspases to initiate cellular 
apoptosis process and (v) reducing the G-protein mediated signalling pathway 
in the ER-negative mammary cancer cell (Figures 1.6 and 1.7 ). The nuclear ER 
interaction is the most widely studied mechanism of phytoestrogen effect. 
Ginsenoside, a phytoestrogenic component extracted from ginseng root, 
preferentially activated ERα via the phosphorylation of a transcription factor  
(AF-1) without the ligand-receptor interaction. However, isoflavones were 
demonstrated to selectively activate ERβ rather than ERα in the breast cancer 
cell line MCF7, indicating a potential ERβ-related mechanism underlying 
protective effect of dietary phytoestrogen against a mammary tumour. Moreover, 
genistein (an isoflavone) might stimulate a self-limiting mechanism of E2-
stimulated ERβ gene expression in breast cancer cells (Zhao & Mu, 2010). In 
addition, oleocanthal (a minor secoiridoid and type of natural phenolic 
compound found in extra-virgin olive oil) has been observed to inhibit invasion 
and migration of human breast (MCF7, MDA-MB-231) and prostate cancer (PC3) 
cell lines. Applying these results to humans suggests that consumption of olive 
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oil phenolics may play a role in reducing metastatic spread in humans (Hashim 
et al., 2014). 
 
 
 
 
 
Figure 1.6  Phytoestrogen (coumestrol) effect on 
breast cancer proliferation   (Zafar, Singh & Naseem, 
2017). 
 
 
 
 
 
 
 
Figure 1.7 Phytoestrogen actions on modulating signalling 
pathways in the breast cancer cell. The arrows and 
hammers respectively present stimulation and inhibition 
TF: transcription factor, ERE: oestrogen responsive 
element.  (Zhao & Mu, 2010). 
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1.11  Aim of this study 
Phytoestrogens have beneficial effects on osteoblast and osteoclast activity and 
some such as genistein have been trialled in the clinic for the treatment of 
prostate cancer. However, while it is clear that PEs have effects on a range of 
cell types, there is little data in the literature on the expression of factors 
associated with preferential metastasis, disrupted remodelling and osteomimicry. 
Some data show a beneficial effect of genistein on markers but other PE have 
been poorly described and combinations typically seen in the diet have not been 
examined. Similarly, an interaction between PE has not been studied. Therefore, 
the proposed study aims to establish the effect of a range of phytoestrogens 
(genistein, daidzein and coumestrol) on cell proliferation, migration and the 
expression of genes with a role in EMT, preferential metastasis and modification 
of bone remodelling (CXCR4, snail, integrin α5, PTHrP, RANKL) and 
osteomimicry (Runx2, osterix and collagen type I) in breast and prostate cancer 
cell lines.  The impact of cytokines associated with bone tumours (BMP-7, TGF-
β and IL-33) on the response to selected PE will also be examined to ascertain 
if a more realistic bone environment alters their activity. 
  
 
36 
 
 
 
 
 
 
 
Chapter two 
 General Materials and Methods 
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2. Materials and Methods 
2.1 Media, reagents and cell culture 
Human MCF7 breast and PC-3 prostate cancer cells obtained from (ATCC, UK) 
were incubated in phenol red-free minimum essential medium or Ham’s F-12 
medium (Gibco ThermoFisher Scientific, UK) supplemented with 10% charcoal 
stripped foetal calf serum That decreased the levels of various hormones  
(Autogen Bioclear, U.K.), 2 mmol/l glutamine, 100 IU/ml benzylpenicillin and 100 
mg/ml streptomycin (all from Sigma-Aldrich, Poole, Dorset, UK). Incubations 
were performed at 37oC in 5% CO2, and cultures fed every 2–3 days by 
replacing half of the culture volume with fresh medium. The non-selective 
oestrogen antagonist ICI 182,780 was obtained from Tocris Biosciences (Bristol, 
UK). All other reagents were obtained from (Sigma-Aldrich, Poole, Dorset, UK) 
unless stated.  
2.2 Cell cryopreservation and reanimation  
Cells of passage 3-7 were cryopreserved and then used for experiments as 
required. In brief, adherent cells were passaged using trypsin-
ethylenediaminetetraacetic acid (EDTA) solution for no longer than 5 minutes at 
37oC. After detachment, cells were washed with the culture medium to 
deactivate trypsin and centrifuged at 1500rpm for 5 minutes at room 
temperature. After centrifugation, cells were resuspended in sterile 90% FCS 
and 10% dimethyl sulphoxide (DMSO) solution, placed in cryopreservation tube 
and frozen at -80°C for 24 hour before transfer to liquid nitrogen for long-term 
storage. To reconstitute frozen cells, vials were removed from liquid nitrogen 
and rapidly thawed and then immediately transferred into 5 ml of cell culture 
media, centrifuged to remove DMSO and then cultured in 25 cm2 flasks until 80% 
confluence was reached. 
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2.3 Measurement of cell viability  
The effect of phytoestrogens on cell viability was assessed using a commercial 
proliferation assay.  Cells were transferred to 96-well plates at a density of 105 
cells per well and cultured with combinations of genistein, daidzein and 
coumestrol (10-5 to 10-9 M) for 72 hours. Viability was then assessed using an 
AQeous one cell viability assay which is a colorimetric technique for indicating 
the number of viable cells in proliferation, cytotoxicity or chemosensitivity 
assays. The CellTiter 96® AQueous One Solution Reagent contains a 
tetrazolium compound [3-(4,5-dimethylthiazol-2-yl)-5-(3-
carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium, inner salt; MTS] and 
an electron coupling reagent (phenazine ethosulfate; PES). PEs has enhanced 
chemical stability, which allows it to be combined with MTS to form a stable 
solution. 
Assays are processed by adding a small volume of the CellTiter 96® 
AQueous One Solution Reagent directly to culture wells, incubating for 1–4 
hours and then recording absorbance at 490nm with a 96-well plate reader. The 
quantity of formazan product as measured by the amount of 490nm absorbance 
is directly proportional to the number of living cells in culture(Promega, UK). Cell 
viability in control cultures was signified as 1 and cell viability was calculated 
relative to this.  Initial studies determined the profile of concentrations able to 
significantly alter viability.  Experiments examining the role of oestrogen 
receptor signalling were performed by incubating cells with combinations of 
phytoestrogens shown to significantly modify viability in the presence of the 
oestrogen antagonist ICI 182,780 (10-5 M). Subsequent experiments examined 
the effect of combining these effective concentrations.  Viability data was 
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normalized to un-treated control values and all assays were performed in 
triplicate.  
2.4 Motility assay 
To examine the effect of phytoestrogens on cell motility, cells were transferred 
to 24-well plates at a density of 105 cells per well and treated with genistein, 
daidzein and coumestrol (10-9  to 10-5 M) for 72 hours. A scratch was then made 
in the middle of each well using a sterile pipette tip. Wells were then washed 
three times in fresh medium to remove non-adherent cells and the cultures 
incubated for a further 48 hours in the presence of phytoestrogens. The 
separation of the edges of the scratch was used to quantify cell motility. To 
enable this, digital images were taken 0, 6, 12, 24 and 42 hours after scratching 
on an inverted microscope (Leica, Germany) fitted with a digital camera 
(Scopetek, DCM-510, China) at x40 magnification. Images were analysed by 
measuring the distance between the edges in mm of the scratch using ImageJ 
analysis software (fig 2.1) (National Institute of Health, USA).  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.1: the wound healing assay technique steps used in the lab to 
study the motility of PC3 and MCF7 cells. 
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2.5 Molecular biology 
2.5.1 RNA extraction and reverse transcription  
Total RNA was isolated using a commercially available GenEluteTM 
mammalian total RNA miniprep kit (Sigma-Aldrich, Poole, Dorset, UK), which 
utilises a column based technique to isolate and purify RNA. After incubation, 
cells were washed with DPBS and total RNA extracted according to the 
manufacturer’s protocol. All consumables and reagents used were free of 
contaminating DNAase and RNAase. Genomic DNA was removed using an on-
column DNase-I treatment step. RNA and DNA quantity and purity were 
measured using a nanodrop spectrophotometer (ND-1000) (Labtech, 
Heathfield ,UK). Absorbance was measured with A260 for nucleic acid and the 
ratio A260:A280 was used to assess sample purity. RNA concentrations were 
then adjusted to 250μg/μl in molecular biology grade H2O, RNA (1μg) was 
reversed transcribed to cDNA using M-MLV reverse transcriptase reaction in 
thin-walled PCR tubes (Sigma-Aldrich, Poole, Dorset, UK) using a GeneAmp 
PCR System 9700 machine. RNA was denatured at 70°C for 10 min in the 
presence of dNTPs (0.5 mM) (dATP, dCTP, dGTP, TTP) and random nanomers 
(1 μM). Reactions were cooled on ice for 5 minutes and then 1 unit of MMLV-
reverse transcriptase was added to each reaction. Reactions were then 
incubated at room temperature for 10 min, 37°C for 50 min and 94°C for 5 min. 
RTs were stored at 4oC until used. Negative controls consisting of reactions 
lacking RT were run in all experiments. 
2.5.2 Verification of PCR primers and RT  
Primers were purchased from Eurofins MWG Operon (Ebersberg, Germany).     
2 μl of cDNA was used for each PCR reaction. Each reaction contained 10 μM 
of forward and reverse primers, dNTPs (0.5 mM), Taq DNA polymerase (5 
41 
 
unit/μl) and PCR buffer (10x) in a final volume of 25 μl. Reaction conditions were 
94oC for 2 minutes, followed by 40 cycles at 95oC for 30 seconds, 60oC for 30 
seconds and 72oC for 30 seconds. Product size and primer specificity where 
then confirmed using agarose gel electrophoresis. PCR samples had 2.5 μl of 
loading buffer (orange G dye) added and was then loaded onto a 2% (w/v) TAE 
agarose gel. Gels were made by dissolving agarose (electrophoresis grade, 
Fisher Scientific, Loughborough,UK) in an appropriate volume of TAE buffer (40 
mM Tris-base, l0 mM EDTA and 0.1% acetic acid) which was heated in a 
microwave for 2 minutes and then cooled to 50°C. 1 μl of ethidium bromide (10 
mg/ml) was then added to the gel to enable visualization of DNA under UV light. 
Gels were run at 60-100V according to the size of the product for an appropriate 
time. Bands were checked for presence and size using UV gel documentation 
system (UVi Tech, Cambridge, United Kingdom) linked to a PC (Toshiba, 
Tokyo,Japan). 
2.5.3 10x Tris-acetate-EDTA (TAE) buffer  
0.4 M Tris-base, 0.5 M EDTA and 1M acetic acid were dissolved in 1 L of d.H2O. 
The pH was adjusted to 8.5 and then diluted to make 1x TAE buffer. 
2.5.4 Real-time quantitative PCR analysis of metastatic marker expression 
Quantitative PCR is an advanced sensitive technique that enables the absolute 
quantification of gene expression in biological samples. This technique used in 
this study to detect the effect of PEs on the gene expression of key mediators of 
preferential metastasis using the CT methodology which is a simple formula 
used in order to calculate the relative fold gene expression of samples when 
performing real-time polymerase chain reaction (Livak & Schmittgen, 2001). 
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MCF7 or PC-3 cells (5 x 105 cells) were incubated in 25 cm2 flasks for               
24 or 72 hours with genistein, daidzein or coumestrol. Total RNA was extracted 
from these cultures using a Sigma GenElute RNA isolation kit and reversed 
transcribed with M-MLV reverse transcriptase using random nanomer primers. 
CT qPCR was performed on a StepOne PCR system (Applied Biosystems, 
Paisley, UK) using the DNA-binding dye SYBR green for detection of PCR 
products. A total of 1 μl of cDNA was added to a final reaction volume of  12.5 μl 
containing 0.05 U/μl Taq, SYBR green and specific primers (0.2 μM). Primers 
used prescribed in table 2.1. 
 5 -´3  ´Forward primer 3 -´5  ´Reverse primer Amplicon 
Human β-actin GCGCGGCTACAGCTTCACCA TGGCCGTCAGGCAGCTCGTA 777-929 
Human Runx2 AGACCCCAGGCAGGCACAGT GCGCCTAGGCACATCGGTGA 816-972 
Human CXCR4 GCGCAAGGCCCTCAAGA GTGCGTGCTGGGCAGAGGTT 1010-1257 
Human Snail CGAGTGGTTCTTCTGCGCTA CTGCTGGAAGGTAAACTCTGGA 27-183 
Human  Integrin 
α5β3 
AATTTTACTGGCGAGCAG TTGGTGGCATGCTTCGAG 1054- 1465 
Human PTHrP GTCTCAGCCGCCGCCTCAA GGAAGAATCGTCGCCGTAAA 693-785 
Human collagen 
type I 
CCTGGCAGCCCTGGTCCTGA CTTGCCGGGCTCTCCAGCAG 1766-1918 
Human  (osx) GGCTCTAGCCCTCTGCGGGA CGTGGGGGTTTGGCTCCACC 459-1123 
 
Table 2.1 primers and their amplicons used in the experiments 
 
The progress of the PCR amplification was monitored by real-time fluorescence 
emitted from SYBR Green during the extension time.  Reaction conditions were 
94oC for 2 minutes, followed by 40 cycles of 95oC for 30 seconds, 60oC for 30 
seconds and 72oC for 30 seconds.  At the end of each PCR run, a melt curve 
analysis was performed to show the absence of non-specific bands.  The 
relative quantification (RQ) value for each group was calculated by the 
instrument’s software using CT values for non-treated controls normalised to the 
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expression β-actin mRNA as the most widely used gene for normalization in the 
experiments of gene expression and to give the correct measurements when 
using the charcoal stripped (Rebouças et al., 2013).  Samples were analysed in 
triplicate and experiments repeated separately three times. 
2.6 Statistical analysis 
Differences between groups were assessed using a Fisher’s post-hoc analysis 
of variance test for pairwise comparisons between means (Statview; Abacus 
concepts, California, USA).  The data corresponded to three independent 
observations from three separate repeats each consisting of three replicates. A 
p-value <0.05 was considered statistically significant.  
 
 
 
 
 
 
 
 
 
  
 
44 
 
 
 
 
 
Chapter Three 
 Individual phytoestrogens are more effective than combinations in 
reducing the viability of prostate and breast cancer cell lines, with no 
individual effect on their motility 
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3.1 Introduction 
It has been suggested in some studies (Bilal et al., 2014; Hwang & Choi, 2015; 
Kyro et al., 2015) that Phytoestrogens, (PEs), a diverse group of plant-derived 
compounds with a structure and a function similar to that of oestradiol, have the 
capacity to reduce the incidence of tumour formation and the rate of cancer 
progression.  In addition to their oestrogenic action, PEs have also been shown 
to inhibit tyrosine kinase and telomerase activity and to alter cellular redox 
status (Hwang & Choi, 2015).  Spinozzi and his team indicated that exposure of 
in vitro cultured Jurkat cells, a T-cell leukemia line, to genistein resulted in a 
dose-dependent, growth inhibition. Cell-cycle analysis of genistein-treated cells 
revealed a G2/M arrest at low genistein concentrations. The imbalances in cell-
cycle control were followed by apoptotic death of genistein-treated cells. 
Immunocytochemical analysis of cells showed that genistein effectively inhibit 
tyrosine kinase activity in cultured Jurkat cells. This indicate that the natural 
isoflavone genistein antagonises tumour cell growth by both cell-cycle arrest 
and induction of apoptosis and suggest that it could be an encouraging new 
agent in cancer therapy (Spinozzi et al., 1994). Epidemiological studies have 
been contradictory, suggesting variously that diets with a high phytoestrogen 
content may promote the risk of prostate and breast cancer, reduce the risk, or 
have no association at all with these forms of cancer (Trock, Hilakivi-Clarke & 
Clarke, 2006; Wu et al., 2008; Yan & Spitznagel, 2009). 
Positive associations have been noted between soy protein intake and reduced 
incidence of breast cancer in both Asian populations, whose diets have a high 
soy content (Wu et al., 2008) and in Westerners given supplements (Trock, 
Hilakivi-Clarke & Clarke, 2006). Other studies, however, contest this assertion, 
and report that high soy consumption in Asian women living in Asia had no 
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effect on breast cancer incidence (Trock, Hilakivi-Clarke & Clarke, 2006). Also,  
the results of meta-analysis of epidemiological studies have indicated that soy 
consumption in Asian populations has no disadvantageous effects on the risk of 
breast cancer recurrence, and in some cases it significantly reduces the risk 
(Magee & Rowland, 2012). Similarly, a six-month isoflavones intervention 
involving Western women increased Ki-67 levels, a marker of proliferation, in 
breast epithelial cells of premenopausal women (Khan et al., 2012).  
On the other hand, dietary soy isoflavones have been shown to stimulate 
metastatic tumour formation in lungs and increased Ki-67 protein expression in 
these metastasised tumours (Yang et al., 2015). In prostate tumours, additional 
factors, including PSA and IGFs, may also increase tumour growth 
(Abrahamsson, 2004).  Genetic predisposition, inflammation and increased cell 
proliferation are some of the pre-element factors for prostate cancer 
commencement. Prostate cancer development depends on the decrease of 
androgen levels until a completely androgen-independent cancer is formed. 
Molecular and pathological analysis of human prostate cancer samples and 
animal model-based researches have both shown that infectious agents, 
oestrogenic hormones, age, race, genetics and other occupational factors can 
damage the prostate epithelium and provoke inflammatory responses leading to 
chronic or recurrent condition of prostate cancer (Joshi et al., 2015). 
Alterations in molecules that regulate the cell cycle and apoptosis offer 
promising avenues for further investigation. P53, p27, p21, and Rb have been 
studied, resulting in variable levels of evidence that they participate in the 
pathogenesis of prostate cancer. In one study, loss of expression of the tumour 
suppressor protein p27 was strongly associated with the development of benign 
47 
 
prostatic hyperplasia, (BPH), whereas variable levels of p27 expression were 
noted in prostate cancers. In addition, there is a high frequency of somatic 
mutations in PTEN, a tumour suppressor gene, which suggests that this may be 
a frequent target for inactivation in sporadic prostate cancers growth factors. 
Their receptors also play an important role in the growth regulation of normal 
and cancerous cells.  Several specific growth factors have been associated with 
the growth and survival of prostate cancer (Oh et al., 2003). It seems that 
several signalling cascades are involved in prostate cancer progression, and 
understanding the key signalling events and their complex inter-relationships 
has become essential to better therapeutic methods (Joshi et al., 2015). 
The interaction of receptors with their specific growth hormone results in cell 
growth and proliferation. The overexpression of either or both growth factors 
and receptors contribute to the consecutive signalling in cancer (Perona, 2006). 
Growth factor TGF-β causes growth arrest of most of the cell types. The 
mechanisms, which differ somewhat between cell types, involve the inhibition of 
the expression of the transcription factors Myc and members of the Id family, 
and induction of the cell cycle inhibitor tumour cells becomes increasingly 
resistant to the cytostatic effects of TGF-β, which is a vital factor in the shift from 
being a tumour suppressor to a tumour promoter. During tumourigenesis, TGF-β 
promotes cell survival and metastasis of breast cancer cells by increased 
expression of the anti-apoptotic factor (DEC1) (Heldin, Landström & Moustakas, 
2009).  
The conflicted nature of the literature may reflect differences between 
menopausal status and short term and long term effects of PE, with earlier 
exposure being more beneficial. It may also reflect interactions between the 
diverse ranges of PE that can be obtained from a diet, which could also impact 
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on the outcome, according to supplementation studies. While it is clear that 
most individuals will be exposed to a range of dietary phytoestrogens, which 
may have contrasting effects, in vitro studies examining the cellular impact of 
PEs have typically assessed the impact of PEs in isolation.  Thus, the current 
study initially investigates the effect of individual and combinations of PEs on 
breast (MCF7) and prostate (PC3) cancer cell lines’ viability to ascertain which 
is more effective after incubation for 72 hours. This is followed by a wound 
healing assay to study the effect of phytoestrogens on motility, and to observe 
whether there is a connection with invasion and metastases of these cell lines. 
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 3.2 Materials and Methods 
 
Methods used here in chapter 3 are similar to what been mentioned in chapter 2 
(materials and methods) for the points: 
2.1 media reagents and cell culture 
2.2 cell cryopreservation and reanimation  
2.3 measurements of cell viability 
2.4 motility assay 
2.6 statistical analyses  
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3.3 Results 
3.3.1 Combinations of phytoestrogens have less effect on viability 
Experiments were undertaken to establish how prostate (PC3) and breast 
(MCF7) cancer cells respond to PE individually, in combination and to non-
selective oestrogen antagonist ICI 182,780. 
PC3 and MCF7 cells were incubated with phytoestrogens for 72 hours to have 
long exposure time of cells to PE. Genistein significantly decreased PC3 and 
MCF7 cell viability, PC3 cells response at 10-7 M was (15%, P = 0.01) and for 
10-6 M was (11%, P = 0.04) (Figure 3.1 A); for MCF7 cells response at 10-6 M 
was (15%, P = 0.04) and for 10-5 M was (25%, P = 0.04) (Figure 3.1 B). 
Daidzein significantly reduced viability of PC3 cells, 10-8 M (18%, P = 0.04) and 
for 10-7 M (22%, P = 0.01) (Figure 3.1 A), whereas it had no effect on MCF7 cell 
viability at any concentration (Figure 3.1 B).  In contrast coumestrol reduced 
MCF7 viability at 10-7 M (29%, P = 0.03,) 10-6 M (34%, P = 0.01) and 10-5 M 
(37%, P = 0.007) (Figure 3.1 B), but had no effect on PC3 cells and increase 
cell proliferation compared to control (Figure 3.1 A). The inhibitory effect of all 
phytoestrogens was reversed by incubating with the oestrogen receptor 
antagonist ICI 182, 780 and this may be related to the effect of endogenous 
oestrogen and to the ER-independent pathway  (Figure 3.2 A and B). 
To determine the nature of any interaction between phytoestrogens the effect of 
incubating cells with combinations of phytoestrogens shown to significantly reduce 
viability was examined.  Surprisingly combinations of phytoestrogens were antagonistic, 
as while individual phytoestrogens reduced viability no significant effect was noted 
when cells were incubated with combinations (Figure 3.3 A and B). In light of this, all 
subsequent studies examined effective concentrations of individual PE rather than 
combinations. 
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Figure 3.1 Effect of phytoestrogens on cell viability. Concentrations of genistein, 
daidzein and coumestrol that significantly reduced A. PC3 and B. MCF7 cell viability. 
Cells were transferred to 96-well plates at a density of 105 cells per well and cultured 
with combinations of genistein, daidzein and coumestrol (10-5 to 10-9 M) for 72 hours. 
Viability was then assessed using an AQueous one cell viability assay (Promega UK) 
according to manufacturer’s instructions. Results are the mean ± SEM for three repeat 
experiments. * P<0.05 ,  ** P<0.01 versus control. 
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Figure 3.2 The non-selective oestrogen antagonist ICI 182,780. (10-5 M) prevents the 
effect of phytoestrogens on cell viability in A. PC3 and B. MCF7 cells. Cells were 
transferred to 96-well plates at a density of 105 cells per well and cultured with 
combinations of genistein, daidzein and coumestrol (10-5 to 10-9 M) and ICI 182,780 for 
72 hours. Viability was then assessed using an AQueous one cell viability assay 
(Promega, UK) according to manufacturer’s instructions. Results are the mean ± SEM 
for three repeat experiments. * P<0.05 and  *** P<0.0001versus control 
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Figure 3.3 The inhibitory effect of phytoestrogens is lost when effective concentrations 
are combined in A. PC3 and B. MCF7 cells. Cells were transferred to 96-well plates at a 
density of 105 cells per well and cultured with effective combinations of genistein, 
daidzein and coumestrol for 72 hours. Viability was then assessed using an AQueous 
one cell viability assay (Promega, UK) according to manufacturer’s instructions. Results 
are the mean ± SEM for three repeat experiments. * P<0.05 versus control.  
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3.3.2 Motility 
As expected, breast and prostate cancer cells closed the scratch within 42 
hours with little to no gap present between the edges of the scratch at this time 
point. In cultures of PC3 cells (Fig 3.4) there was little effect of phytoestrogens 
on the rate of closure with only one statistically significant effect noted with 
daidzein (10-7 M) and was (33%, P = 0.01), which promoted the rate of closure 
at 12 hours table (3.2). Genistein and daidzein had no significant effect on 
MCF7 motility  table (3.1), whereas coumestrol (Fig 3.5) significantly decreased 
scratch width at 6 hours for 10-8 M (70%, P = 0.02), 10-7 M (68%, P = 0.003) and  
10-6 M (71%, P = 0.04); at 12 hours for 10-7 M (51%, P = 0.01) and 10-6 M (53%, 
P = 0.04); and for 24 hours the effect was from concentrations (10-9 to 10-5 M) 
and was for 10-9 M (33%, P = 0.01), 10-8 M (30%, P = 0.002), 10-7 M (24%, P = 
<0.0001)10-6 M (28%, P = 0.0005) and  for 10-5 M was (35%, P = 0.03) (Table 
3.1 B). 
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Figure 3.4: showing the growth of the PC3 cells and closure of the scratch at 0 time and 
after 6, 12, 24 and 42 hours.  
 
 
56 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.5: showing the growth of the MCF-7 cells and closure of the scratch at 0 time 
and after 6, 12, 24 and 42 hours.  
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Table 3.1 Coumestrol significantly increases the rate of wound closure of MCF7 cells in a scratch 
assay. 
 
 
 
 
MCF7 cells were treated with genistein, daidzein and coumestrol for 72 hours. A scratch was then made in the middle of 
wells using a sterile pipette tip. Digital images were taken after scratching on an inverted microscope (Leica, Germany) 
fitted with a digital camera (Scopetek, DCM-510, China) at x40 magnification. The separation of the edges of the scratch 
was used to quantify motility by measuring the distance between the edges in mm using ImageJ analysis software (National 
Institute of Health, USA). * P<0.05 versus control. (A) daidzein, (B) coumestrol and (C) genistein. 
Concentrations 
( M ) 
 
Scratch 
width 
6 hr 
(mm) 
SEM 
Scratch 
width 
12 hr 
(mm) 
SEM 
Scratch 
width 
24 hr 
(mm) 
SEM 
Scratch 
width 
42 hr 
(mm) 
SEM 
Control 0.77 0.02 0.62 0.03 0.41 0.04 0.20 0.03 
-9 M 0.80 0.05 0.66 0.06 0.47 0.06 0.28 0.07 
-8 M 0.74 0.03 0.60 0.03 0.36 0.03 0.19 0.02 
-7 M 0.72 0.02 0.53 0.03 0.34 0.04 0.15 0.03 
-6 M 0.72 0.02 0.52 0.02 0.28 0.03 0.11 0.03 
-5 M 0.78 0.03 0.62 0.04 0.37 0.04 0.20 0.04 
Concentrations 
( M ) 
 
Scratch 
width 
6 hr 
(mm) 
SEM 
Scratch 
width 
12 hr 
(mm) 
SEM 
Scratch 
width 
24 hr 
(mm) 
SEM 
Scratch 
width 
42 hr 
(mm) 
SEM 
Control 0.76 0.02 0.61 0.03 0.45 0.05 0.20 0.04 
-9 M 0.71 0.03 0.60 0.05 0.33 0.05 * 0.17 0.05 
-8 M 0.70 0.02 * 0.57 0.02 0.30 0.03 * 0.18 0.02 
-7 M 0.68 0.02 * 0.51 0.03* 0.24 0.03 * 0.15 0.02 
-6 M 0.71 0.01* 0.53 0.02* 0.28 0.02* 0.16 0.02 
-5 M 0.75 0.02 0.59 0.03 0.35 0.03* 0.15 0.03 
Concentrations 
( M ) 
 
Scratch 
width 
6 hr 
(mm) 
SEM 
Scratch 
width 
12 hr 
(mm) 
SEM 
Scratch 
width 
24 hr 
(mm) 
SEM 
Scratch 
width 
42 hr 
(mm) 
SEM 
Control 0.76 0.02 0.64 0.03 0.39 0.04 0.18 0.04 
-9 M 0.75 0.02 0.64 0.03 0.42 0.05 0.22 0.04 
-8 M 0.78 0.02 0.63 0.03 0.43 0.04 0.18 0.03 
-7 M 0.76 0.02 0.60 0.02 0.41 0.04 0.17 0.03 
-6 M 0.81 0.02 0.66 0.03 0.45 0.04 0.17 0.03 
-5 M 0.75 0.02 0.58 0.03 0.37 0.04 0.14 0.03 
A 
C 
B 
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Table 3.2 shows there was no effect of coumestrol and genistein on wound clouser just for 
daidzein after 12 hours in PC3 cell culture in the scratch assay. 
 
 
PC3 cells were treated with genistein, daidzein and coumestrol for 72 hours. A scratch was then made in 
the middle of wells using a sterile pipette tip. Digital images were taken after scratching on an inverted 
microscope (Leica, Germany) fitted with a digital camera (Scopetek, DCM-510, China) at x40 
magnification. The separation of the edges of the scratch was used to quantify motility by measuring the 
distance between the edges in mm using ImageJ analysis software (National Institute of Health, USA). * 
P<0.05 versus control. (A) daidzein, (B) coumestrol and (C) genistein. 
Concentrations 
( M ) 
 
Scratch 
width 
6 hr 
(mm) 
SEM 
Scratch 
width 
12 hr 
(mm) 
SEM 
Scratch 
width 
24 hr 
(mm) 
SEM 
Scratch 
width 
42 hr 
(mm) 
SEM 
Control 0.63 0.06 0.52 0.07 0.32 0.08 0.18 0.06 
-9 M 0.69 0.05 0.52 0.06 0.33 0.07 0.22 0.07 
-8 M 0.60 0.03 0.45 0.05 0.29 0.07 0.10 0.04 
-7 M 0.58 0.04 0.33 0.06* 0.15 0.05 0.11 0.07 
-6 M 0.69 0.05 0.50 0.06 0.23 0.06 0.13 0.05 
-5 M 0.61 0.04 0.40 0.06 0.25 0.06 0.10 0.04 
Concentrations 
( M ) 
 
Scratch 
width 
6 hr 
(mm) 
SEM 
Scratch 
width 
12 hr 
(mm) 
SEM 
Scratch 
width 
24 hr 
(mm) 
SEM 
Scratch 
width 
42 hr 
(mm) 
SEM 
Control 0.54 0.03 0.38 0.04 0.17 0.03 0.06 0.03 
-9 M 0.58 0.03 0.40 0.03 0.22 0.04 0.04 0.03 
-8 M 0.57 0.03 0.41 0.03 0.17 0.03 0.09 0.05 
-7 M 0.53 0.03 0.36 0.03 0.14 0.03 0.05 0.03 
-6 M 0.57 0.03 0.33 0.02 0.20 0.04 0.11 0.05 
-5 M 0.56 0.03 0.36 0.03 0.19 0.03 0.03 0.02 
Concentrations 
( M ) 
 
Scratch 
width 
6 hr 
(mm) 
SEM 
Scratch 
width 
12 hr 
(mm) 
SEM 
Scratch 
width 
24 hr 
(mm) 
SEM 
Scratch 
width 
42 hr 
(mm) 
SEM 
Control 0.60 0.03 0.47 0.03 0.26 0.04 0.08 0.03 
-9 M 0.58 0.03 0.43 0.03 0.23 0.04 0.11 0.03 
-8 M 0.62 0.03 0.51 0.04 0.30 0.03 0.10 0.03 
-7 M 0.66 0.02 0.51 0.03 0.22 0.04 0.06 0.02 
-6 M 0.58 0.04 0.44 0.04 0.26 0.06 0.07 0.02 
-5 M 0.57 0.03 0.42 0.04 0.25 0.05 0.11 0.04 
A 
B 
C 
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3.4 Discussion 
There is conflicting data in the literature regarding the effect of phytoestrogens 
on breast and prostate cancer. Studies indicate variously that diets rich in 
phytoestrogens or phytoestrogen supplementation can have beneficial or 
detrimental effects on risk, cell viability and gene expression (Bilal et al., 2014).  
While many previous studies have examined the effect of individual 
phytoestrogens, there is little data on the impact of combinations of 
phytoestrogens, studies in which PE with different variables have been 
combined (Charles et al., 2007) or studies focussing on genomic effects (Dip et 
al., 2009).  These areas are worthy of further investigation, as it is highly likely 
that individuals are exposed to many PE at different concentrations, due to the 
varied nature of PE obtained from dietary sources.  Even with supplementation 
with distinct PE, individuals will still be receiving a range of PE, which could 
modify the action of the supplement.  This study indicates that while genistein, 
daidzein and coumestrol reduce breast and prostate cell viability individually in 
an oestrogen receptor dependent manner, this beneficial action is lost when 
previously effective concentrations are combined. Antagonism between 
chemotherapeutic agents is not a novel phenomenon: genistein has been 
shown to modulate the anti-proliferative effect of cisplatin on breast and colonic 
tumour cells. Genistein at 10-4 M inhibits cell growth and induces apoptosis in 
breast cancer MCF7 cells and colon cancer cells HT29. In contrast, co-
treatment of genistein with the same concentration of 10-4 M with cisplatin 
results in an additive effect and abolishes the anti-proliferative effect of cisplatin 
on breast and colon cancer cells. (Hu et al., 2014). It has also been reported to 
induce resistance to doxorubicin and mitoxantrone by increasing ABC 
transporter expression, which increases the expulsion of the tumour 
suppression drugs from the cells (Rigalli et al., 2016). The basis of the 
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antagonistic action observed in the current study is not known, but in the light of 
the concentration-dependent effect on viability may relate to combinations 
exceeding effective concentration windows. For example, no PE reduced 
viability at 10-5 M, but a significant effect was noted with 10-6 M genistein. 
Exposing cells to additional PE in the presence of 10-6 M genistein would, 
therefore, be expected to reduce viability as overall concentrations rise. The 
work of Choi supports this, and the biphasic concentration-dependent effects of 
genistein and daidzein noted in these studies were attributed to differential 
actions, mediated through ER (Choi & Kim, 2013).  In the current study, the 
inhibitory effect of PEs was also ER-dependent, as it was prevented by a non-
selective oestrogen antagonist. It is not clear, however, whether this action was 
mediated through ERα or through β, which have opposing actions on breast and 
prostate cell viability (Omoto & Iwase, 2015). While ERα is typically associated 
with greater proliferation and increased tumour burden in breast and prostate 
cancer, overexpression of ER β in vitro reduces oestrogen-driven proliferation 
and tumour formation (Paruthiyil et al., 2004). Similarly, in clinical studies, ERβ 
expression has been shown to correlate with increased proliferation and higher 
grade invasive tumours in breast cancer (Huang et al., 2014).  While evidence 
supports a beneficial effect of ERβ and a detrimental effect of ERα, there is 
added complication due to splice variants with opposing actions on tumour cell 
activity (Dey et al., 2012). ER β1 is often lost in advanced cases and has a 
tumour suppressive action, whereas ER β2 is elevated in more advanced cases 
and promotes proliferation (Dey et al., 2012). Thus, there is a crosstalk between 
ER influences transcription of ER responsive genes through the receptors own 
intrinsic activity and competition for binding to oestrogen-responsive DNA 
elements. Thus, oestrogen receptor dependent ligands, such as phytoestrogens, 
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induce a unique cellular response that is determined by their specific affinity for 
ER variants, and modified by the presence of other ER binding ligands.  
Phytoestrogens have differential binding affinities for ER α and β.  Studies have 
indicated that genistein and daidzein have a significantly higher affinity for ER 
beta than coumestrol, which has similar affinities for ER α and β (Harris et al., 
2005; Kostelac, Rechkemmer & Briviba, 2003). However, data on phytoestrogen 
affinities for splice variants is lacking in breast and prostate cancer is lacking, 
and it is possible that they have significantly different EC50. Thus, the 
antagonistic response seen in the current study could arise due to crosstalk 
between ER signalling and differences between proliferative and apoptotic 
actions.  
Phytoestrogens have additional ER-independent effects that modify mitosis and 
cell death. These include changes in redox status and inhibition of tyrosine 
kinase activity (Lee et al., 2012; Ullah et al., 2016; Zafar, Singh & Naseem, 
2016). Therefore, an alternative explanation for the antagonistic effect is that it 
is due to crosstalk between ER dependent and independent actions. Whatever 
the explanation, it is clear from the present data that individual PEs are more 
effective than combinations in reducing cancer cell viability. This antagonism 
may, in part, explain the lack of consensus within the literature, as absolute 
control of dietary PE sources is unfeasible.  This has important implications for 
their clinical utilisation. The overall dietary profile and an individual’s ER status 
should be considered as part of any supplementation strategy to maximise a 
response. 
 
 
 
62 
 
One of the limitations of the wound healing assay, however, was the non-use of 
more sophisticated techniques, such as like biomimetic hydrogels, microchannel 
devices, grooved substrates, microcontact-printed and micropatterned lines, 
vertical confinement devices and micropost arrays. .  
This study shows that PEs have a varied effect on breast and prostate cancer 
cells in vitro, with genistein showing the greatest potential.  In contrast to 
daidzein and coumestrol, it reduced viability in both breast and prostate cancer 
cells, and had a broader effect on gene expression. However, not all the effects 
of coumestrol were beneficial, it increased breast cancer mobility, which could 
enhance the metastatic potential of primary breast cancer cells.  
The results of this study suggest that some of the conflicting data in the 
literature may have arisen due to differences in the concentration and types of 
dietary PE present and stages of tumour development. If PEs are to be 
considered as having potential for reducing the incidence or severity of breast 
and prostate cancer, then further analysis of each individual’s phytoestrogen 
intake and ER status should be considered. 
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3.5 summary of chapter 3 results  
 
Table 3.5.1 Summary of PEs effect on PC3 in individual treatment 
 
Concentration  
(M) 
Genistein Coumestrol Daidzein 
% of 
control 
P Value % of 
control 
P Value % of 
control 
P Value 
10-9 87 0.17 107 0.43 84 0.06 
10-8 93 0.47 106 0.48 82 * 0.04 
10-7 85  *  0.01 107 0.46 78  * 0.01 
10-6 89  * 0.04 109 0.31 89 0.19 
10-5 97 0.70 101 0.92 91 0.27 
 
Note: “    “ , “     “ and “         “ means upregulation, down-regulation and little or no 
modulation of the indicated target respectively. * P<0.05 versus control. 
 
 
 
 
 
 
Table 3.5.2 Summary of PEs effect on MCF7 in individual treatment 
 
Concentration 
(M) 
Genistein Coumestrol Daidzein 
% of 
control 
P Value % of 
control 
P 
Value 
% of 
control 
P Value 
10-9 120 0.42 92 0.56 120 0.22 
10-8 116 0.51 89 0.13 110 0.54 
10-7 103 0.88 29  * 0.03   94 0.70 
10-6 85  * 0.04 66  * 0.01   84 0.32 
10-5 75  * 0.04 63  ** 0.007  78 0.19 
 
 
Note: “    “, “      “and “         “ means upregulation, down-regulation and little or no 
modulation of the indicated target respectively. * P<0.05, ** P<0.01 versus control 
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Table 3.5.3 Summary of PEs effect on PC3 with non-selective oestrogen 
modulator antagonist ICI 182,780 
 
 
Concentration (M) % of control P Value 
Gen 10-6 + ICI 10-5 140 *** 0.001 
Gen 10-7 + ICI 10-5 142 *** 0.0009 
Daid 10-7+ ICI 10-5 139 *** 0.001 
Daid 10-8+ ICI 10-5 124 0.05 
ICI 10-5 153 *** 0.001 
 
 
Note: “    “  means upregulation of the indicated target. *** P<0.001 versus control. 
 
 
 
 
 
Table 3.5.4 Summary of PEs effect on MCF7 with non-selective oestrogen 
modulator antagonist ICI 182,780 
 
Concentration (M) % of control P Value 
Gen 10-5 + ICI 10-5 106 0.23 
Gen 10-6 + ICI 10-5 143 0.64 
Cou 10-5 + ICI 10-5 106 0.74 
Cou 10-6 + ICI 10-5 114 0.79 
Cou 10-7 + ICI 10-5 94 0.66 
ICI 10-5 101 0.98 
 
Note: “    “, “      “and “         “ means upregulation, down-regulation and little or no 
modulation of the indicated target respectively.  
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Table 3.5.5 Summary of PEs effect on PC3 in combination of the effective 
individual treatment 
 
 
Concentration (M) % of control P Value 
Gen 10-6 + Daid 10-7 100 0.99 
Gen 10-6 + Daid 10-8 98 0.88 
Gen 10-7 + Daid 10-7 105 0.69 
Gen 10-7 + Daid 10-8 115 0.20 
 
Note: “    “, “      “and “         “ means upregulation, down-regulation and little or no 
modulation of the indicated target respectively.  
 
 
 
 
 
 
 
 
Table 3.5.6 Summary of PEs effect on MCF7 in combination of the effective 
individual treatment 
 
 
Concentration (M) % of control P Value 
Gen 10-5 + Cou 10-5 97 0.79 
Gen 10-5 + Cou 10-6 83 0.12 
Gen 10-5 + Cou 10-7 101 0.93 
Gen 10-6 + Cou 10-5 92 0.49 
Gen 10-6 + Cou 10-6 100 0.97 
Gen 10-6 + Cou 10-7 102 0.85 
 
Note: “    “, “      “and “         “ means upregulation, down-regulation and little or no 
modulation of the indicated target respectively.  
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Chapter Four 
 Transforming growth factor-β (TGF-β) and bone morphogenic 
protein 7 (BMP7) interfere with the effect of phytoestrogens in breast 
and prostate cancer cell lines 
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4.1 Introduction  
After studying the effect of individual phytoestrogens on the viability of prostate 
and breast cancer cells, this chapter will study their effect on gene expression 
and in the presence or absence of cytokines typical of that seen in the bone 
microenvironment. The transforming growth factor-β (TGF-β) family of cytokines 
has 33 members in humans, including TGF-β isoforms, activins, bone 
morphogenetic proteins (BMPs), and growth and differentiation factors (GDFs). 
These control cell growth, survival, migration and differentiation, and have 
significant roles during embryonic development and adult tissue homeostasis 
(Heldin, Vanlandewijck & Moustakas, 2012). TGF-β family members are 
involved in fibrotic conditions, cancer and autoimmune disease As a regulatory 
'switch', it can, in combination with other cytokines, can 'reprogramme' effector T 
cell differentiation along different pathways (Veldhoen et al., 2008); enhance the 
proliferation of mouse CD8+; increase TNF-a; and accelerate T-cell death (Wan 
& Flavell, 2008). In carcinogenesis, TGF-β has a dual role; originally it 
represses tumorigenesis by inducing growth arrest and promoting apoptosis. In 
advanced cancers, however, where TGF-β is often overexpressed, it promotes 
tumorigenesis by induction of epithelial-mesenchymal transition (EMT), whereby 
tumour cells become more invasive and prone to form metastases. The tumour-
promoting effects of TGF-β also introduce effects on non-malignant cells; 
promoting angiogenesis (Heldin, Vanlandewijck & Moustakas, 2012) and 
inhibiting the production of IL-2, a chemokine known to potently activate T cells, 
and this suppresses immune monitoring cells, such as NK, CD4+ and CD8+  
(Kehrl et al., 1986; Ribatti, 2017). 
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Growth factors, including TGF-β, liberated during the bone destruction 
associated with breast and prostate cancer, acts on cancer cells to induce a 
positive feedback response, in which matrix factors induce the production of 
additional osteolytic factors such as PTHrP, IL-6 and IL-11, which in turn 
stimulate more osteoclastic resorption and increase TGF-β release. Therefore, 
TGF-β plays a central role in this vicious cycle of bone metastasis and, 
consequently, the TGF-β signalling pathway in tumour cells and its cross talk 
within the bone microenvironment present an attractive therapeutic target (Dorai 
et al., 2014). 
Since metastasis is the primary cause of cancer lethality, a wider understanding 
of the mechanisms that promote metastasis is required. TGF-β signaling has 
been linked to the process of metastasis in many cancer types, including those 
of the breast, prostate and lung. Moreover, TGF-β signaling is triggered in PCa 
bone metastatic patients because TGF-β is one of the most abundant growth 
factors in bone and is released during osteoclastic bone resorption. In breast 
cancer bone metastases, TGF-β enhance the expression of genes that shown 
to be associated with bone metastases, including PTHrP, IL-11, CTGF, CXCR4, 
and MMP1(Nguyen, Bos & Massagué, 2009). Evidence supports the concept 
that EMT encourages invasiveness and intravasation into lymph or blood 
vessels of cancer cells as one of the early manifestations of metastasis (Thiery 
et al., 2009). In addition to the direct effects of EMT on cancer cells, invasive 
tumour cells that started EMT secrete many growth factors and chemokines that 
promote and recruit stromal cells, facilitating migration and intravasation of the 
tumour cell. Regarding TGF-β, it is important to know whether TGF-β continues 
to play an active role during additional steps in the pathway that guides tumour 
cells to form metastases (Heldin, Vanlandewijck & Moustakas, 2012). Further 
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investigations are required in order to augment our knowledge of the dynamics 
and interactions that exist between EMT and MET programmes in regulating cell 
reprogramming, and to determine the therapeutic potential of targeting these 
differences (Morrison, Parvani & Schiemann, 2013). 
Bone morphogenetic proteins (BMPs) are members of the TGF-β superfamily, 
and are known to be strong inducers of bone formation. More than 30 BMP-
related proteins have been recognized. They are synthesized by skeletal cells, 
and have an important role in early embryogenesis, skeletogenesis and in the 
maintenance of bone mass in the mature skeleton. They play a role in the 
differentiation of marrow stromal cells toward osteoblasts, chondrocytes and 
adipocytes, and also in a variety of extraskeletal tissues, particularly in vascular 
and neural development and diseases (Biver, Hardouin & Caverzasio, 2013). 
BMP receptors activate intracellular signalling pathways. Smad is the major 
route, in which phosphorylated Smad 1/5/8 form heterocomplexes with Smad 4, 
which then translocate to the nucleus. Nuclear Smad complexes control 
transcription of BMP target genes by binding to sequence motifs in the promoter 
regions of BMP-responsive genes, and through interaction with transcription 
factors or transcriptional co-activators and/or repressors (Attisano & Wrana, 
2002; Miyazono, 1999). In breast cancer cells, BMP7 induces different 
phenotypic changes. The capacity of BMP7 to dramatically stimulate breast 
cancer cells is displayed in MDA-MB-231 cells, in which a remarkable increase 
in cell growth, migration, and invasion was detected. Thus, it is concluded that 
BMP7 has a substantial impact on breast cancer cells and is an important factor 
determining breast cancer responses in bone (Alarmo et al., 2009).  
BMP7 indirectly control the expression of important genes involved in promoting 
the EMT process by ZEB1, ZEB2, Snail1, Snail2, N-cad and Vimentin, by 
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abolishing TGFβ-induced activation of theses genes. Also, BMP7 significantly 
abolished TGFβ-induced suppression of E-cadherin, suggesting a possible 
antagonising effect of BMP7 against TGFβ-mediated EMT in breast cancer cells 
(Ying, Sun & He, 2015). Buijs and co-workers showed that, in prostate cancer 
cells, bone morphogenic protein-7, (BMP7), is an antagonist of the TGF-β and 
can inhibit osteolytic metastases that are characteristic of prostate cancer in 
vivo. Buijs showed that while TGF-β alone decreases E-cadherin expression 
and generates epithelial mesenchymal transition, (EMT), in prostate cancer 
cells which facilitate the invasive and metastatic phenotype, a combination of 
TGF-β and BMP7 promote E-cadherin expression and enhance the epithelial 
phenotype and repress the development of prostate cancer bone metastases 
(Buijs et al., 2007a; Buijs et al., 2007b; Buijs et al., 2007c). In prostate cancer 
cell line LNCaP, BMP7 promotes an epithelial phenotype by increasing E-
cadherin expression, decreasing proliferation, and vimentin expression which is 
a marker of mesenchymal cells (Morrissey et al., 2010). 
BMP pathways have been correlated with mechanisms determining the 
osteoclastic and osteoblastic response to cancer metastases. BMPs and their 
receptors are expressed by human cancer cell lines and human biopsy 
specimens from bone metastatic sites (especially BMP-2, 4, 6 and 7), with clear 
effects on proliferation, migration and invasion of tumour cells, and expression 
pattern, according to the primary cancer (Biver, Hardouin & Caverzasio, 2013). 
BMP -2, -4, and -7 are generally expressed in breast and prostate cancers, and 
mostly BMP7 in breast cancer. Other cell line specific differential expression of 
BMPs is observed in gastric and colon adenocarcinoma. Expression of Bone 
morphogenic protein receptors (BMPRs) (type I and type II) has been noticed in 
various prostate cancer cell lines and tissues. Other BMPRs such as BMP type 
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1A, 1B and II are also expressed in lung cancer and osteosarcoma (Singh & 
Morris, 2010) 
Lack of BMP7 expression by the cancer cells, or resistance of these cells to the 
BMP7 produced by the surrounding normal epithelial or stromal cells drives the 
malignant cells to operate with a TGF-β bias, promoting loss of E-cadherin 
expression and metastasis (Dorai et al., 2014). BMP7 inhibits bone metastasis 
formation in vivo and decreased BMP7 expression has been shown in primary 
breast cancer. Daily BMP7 treatment to nude mice inhibited the growth of 
prostate cancer cells in bone, suggesting that BMP7 and TGF-beta have 
important impacts on the outcome of prostatic metastases in bone (Biver, 
Hardouin & Caverzasio, 2013). 
Most of the literature and a majority of researchers have not focussed 
particularly on the relation of phytoestrogens and BMP-7 in prostate and breast 
cancer in their studies, although there may be  ongoing investigations in this 
area that have yet to be announced. For this reason, it was a challenge to 
decide working on this relation here in this chapter that focused on BMP-7 in 
prostate and breast cancer cell lines in the presence of phytoestrogens. 
Unfortunately, there are no direct studies that combine the PEs/TGF/BMP-7 
model and compare the responses of the prostate cell lines and the breast 
cancer cell lines.   
As shown with individual PEs it appears to be more effective than combinations 
on the viability of prostate and breast cancer cells.  In this chapter, there will be 
a detailed observation of their impact on genes involved in the disease process, 
and attempts will be made to replicate more closely the cytokines (TGF-β and 
BMP7) that these cells would experience in-vivo, in order to see whether this 
modulates the response to individual PEs. 
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Therefore, the effect of PEs on breast and prostate cancer expression of genes 
involved in preferential metastasis to the skeleton will be investigated. Also in 
this chapter, there will be an attempt to model the status that the cells would 
experience in the bone microenvironment and to discover whether the PEs 
would still have an effect similar to that of their individual effect in the presence 
of TGF- β and BMP7 cytokines. Further, the chapter will study the possible 
effect on genes that are important in the EMT process (Integrin α5β3) and 
osteomimicry (Runx2, Osx and collagen type I) in PC3 cells as runx2 has been 
proposed to mediate gene expression and associated with increased motility 
and invasiveness of PCa cells, and the aggressiveness of osteolytic bone 
disease that occur with PCa metastasis to bone (Akech et al., 2010). It will also 
study these cytokines as a model of what prostate and breast cancer cells may 
encounter in the presence and absence of PEs and the expression of genes 
involved in EMT (Snail and Integrin α5β3) and bone vicious cycle (PTHrP and 
collagen type I) in MCF7 cells as PTHrP expression was investigated as 
previous studies have proposed that production of PTHrP is more common in 
metastatic breast cancer cells in bone than in the primary tumour and may be 
responsible for the local bone destruction taking place in patients with breast 
cancer (Guise et al., 1996). Also collagen type I is regarded as simply a physical 
barrier against cancer invasion and tumour cells migration and the essential for 
tumour invasion is collagen degradation, for which matrix metalloproteinases 
(MMPs) play an important role (Fang et al., 2013). 
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4.2 Materials and methods 
Methods used here in chapter 4 are similar to what has been mentioned in chapter 2 
(materials and methods) for the points: 
2.5.1 RNA extraction and reverse transcription  
2.5.2 Verification of PCR primers and RT  
2.5.3 10x Tris-acetate-EDTA (TAE) buffer  
2.5.4 Real-time quantitative PCR analysis of metastatic marker expression 
2.6 Statistical analysis 
4.2.1 cytokines 
Recombinant Human TGF-β1 (Human Cells) and Purified recombinant protein 
of Human bone morphogenetic protein 7 (BMP7) was purchased from Insight 
Biotechnology Limited (Wembley Middlesex, United Kingdom). Concentrations 
used for the cytokines TGFβ and BMP7 were 0.1 ng/mL(Vo et al., 2013) and 30 
ng/mL  (Chen et al., 2014) respectively.  
  
Table 4.1 PCR primers and their amplicons used with individual phytoestrogens, TGF-β 
and BMP7 experiments 
 5 -´3  ´Forward primer 3 -´5  ´Reverse primer  
Human β-actin GCGCGGCTACAGCTTCACCA TGGCCGTCAGGCAGCTCGTA 777-929 
Human Runx2 AGACCCCAGGCAGGCACAGT GCGCCTAGGCACATCGGTGA 816-972 
Human CXCR4 GCGCAAGGCCCTCAAGA GTGCGTGCTGGGCAGAGGTT 1010-1257 
Human Snail CGAGTGGTTCTTCTGCGCTA CTGCTGGAAGGTAAACTCTGGA 27-183 
Human  Integrin  
α5β3 
AATTTTACTGGCGAGCAG TTGGTGGCATGCTTCGAG 1054- 1465 
Human PTHrP GTCTCAGCCGCCGCCTCAA GGAAGAATCGTCGCCGTAAA 693-785 
Human collagen 
type I 
CCTGGCAGCCCTGGTCCTGA CTTGCCGGGCTCTCCAGCAG 1766-1918 
Human  (osx) GGCTCTAGCCCTCTGCGGGA CGTGGGGGTTTGGCTCCACC 459-1123 
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4.3 Results 
4.3.1 Expression of genes involved in metastasis 
The effect of phytoestrogens on expression of genes associated with epithelial 
to mesenchymal transition (snail), preferential metastasis (CXCR4 and integrin 
α5β3) and disruption of bone remodelling (Runx2 as mechanistically linked to 
androgen responsive pathways that support prostate cancer cell growth and 
PTHrP as breast cancer cells in bone express parathyroid hormone-related 
protein (PTHrP) more frequently) was determined by quantitative PCR. 
Genistein (10-7 - 10-6 M) significantly reduced PC3 snail expression at 24 hours 
was (30%, P = 0.02) and (36%, P = 0.02) at 72 hours for genistein 10-6 M and for 
genistein 10-7 M the reduction in expression for snail was (25%, P = 0.02) at 24 
hours and (2%, P = 0.002) at 72 hours (Figure 4.1 A), CXCR4 and integrin α5β3 
expression were also significantly reduced at 24 (1%, P = 0.005) and (11%, P = 
0.0002) at 24 hours and (3%, P = <0.0001) and (13%, P = 0.002) at 72 hours for 
genistein 10-6 M, respectively, and for 10-7 M the reduction in expression was 
significant only at 24 hours (2%, P = <0.005) for CXCR4 and (20%, P = 0.0005) 
for Integrin α5 (Figure 4.1 B and D).  Genistein had a bimodal effect on PC3 
Runx2 expression reducing expression at the earliest time point (11%, P = 
<0.0001) for 10-6 M and (20%, P = 0.0001) for 10-7 M and significantly increasing 
expression at 72 hours (10-7 M) (160%, P = <0.47) for 10-6 M and (282%, P = 0.4) 
for 10-7 M probably because of the oestrogen receptor availability during the 24 
hour and become less available after 72 hour (Figure 4.1 C). Daidzein also 
reduced gene expression in a dose and time dependent manner in PC3 cells, 
significantly decreased snail, CXCR4, integrin α5β3 and Runx2 expression.  
The effect of daidzein (10-7 - 10-8 M) was more pronounced at later time points 
and was (27%, P = <0.01) for snail and (4%, P = 0.0001) for CXCR4 and (7%, P 
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= <0.04) for Integrin α5 for 10-7 M (Figure 4.1 A, B and D) and for 10-8 M the 
reduction was (18%, P = <0.006) for snail and (3%, P = 0.0001) for CXCR4 and 
(9%, P = <0.01) for Integrin α5β3. Apart from Runx2 expression where a 
significant decrease was only noted at 24 hours for daidzein (10-7 - 10-8 M) and 
was (14%, P = <0.0001) and (18%, P = <0.0001) respectively (Figure 4.1 C). 
In MCF7 cells, genistein significantly suppressed CXCR4 and integrin α5β3 
expression at all concentrations and time points and was (42%, P = 0.0004) and 
(50%, P = 0.01) at 24 hours for (10-6  - 10-5 M) respectively for CXCR4 except for 
genistein 10-5M after 72 hour and was (61%, P = 0.08) (Figure 4.3 B), for 
Integrin α5β3 the reduction in expression was for both genistein (10-6 - 10-5  M) 
at 24 and 72 hours and was (12%, P = 0.0001) and (0%, P = <0.0001), 
respectively, and at 72 hours was (12%, P = <0.0001) and (9%, P = <0.0001) for 
(10-6 and 10-5 M), respectively. Coumestrol also significantly reduced integrin 
α5β3 at 24 and 72 hour for Coumestrol (10-7 , 10-6 and 10-5M ) and was (0%, P = 
<0.0001) , (6%, P = <0.0001) and (19%, P = <0.0001) for 24 hours ,respectively, 
and the reduction at 72 hours was (14%, P = <0.0001) , (16%, P = <0.0001) and 
(7%, P = <0.0001)  respectively(Figure 4.2C).  For the reduction in CXCR4 
expression was at 24 hours only in Coumestrol (10-7 , 10-6 and 10-5M ) and was 
(53%, P = <0.001) , (23%, P = <0.0001) and (9%, P = <0.0001) respectively 
(Figure 4.2 B).  Genistein had a differential effect on MCF7 snail and PTHrP 
expression that significantly increased at 10-6  and 10-5  M after 24 hours (329%, 
P = <0.0001) and (495%, P = <0.0001), respectively, for snail and for PTHrP the 
increase was not significant and was (126%, P = 0.84) and (179%, P = 0.3) for 
10-6  and 10-5  M respectively, then a suppressive expression at 72 hours was 
significant in snail for 10-6  and 10-5  M and was (20%, P = <0.0001) and (34%, P 
= 0.0003), respectively, but was not significant decrease in PTHrP and was 
 
76 
 
(67%, P = 0.74) and (11%, P = 0.29) for 10-6  and 10-5 M respectively (Figure 4.2 
A and D).  Coumestrol  decreased PTHrP and snail genes expression after 24 
and 72 hours for 10-6 M and 10-5 M but not  to a significant levels and was higher 
at 10-7 M for both snail and PTHrP at 24 and 72 hours (305%, P = 0.0001), 
(126%, P = 0.08) and (180%, P = 0.27) (127%, P = 0.04) respectively(Figure 4.2 
A and D). 
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Figure 4.1 PC3 cells genes expression with individual phytoestrogens. Concentrations 
of genistein and daidzein shown to reduce cell viability also modify the expression of 
genes implicated in EMT (snail), preferential metastasis (CXCR4 and integrin α5β3) 
and osteomimicry (Runx2) in PC3 cells. Cells were cultured with genistein or daidzein 
for 24 or 72 hours prior to mRNA isolation. Gene expression was then assessed using 
cT qPCR and the DNA-binding dye SYBR green for detection of PCR products. The 
relative quantification (RQ) value for each group was calculated using CT values for 
non-treated controls normalized to the expression β-actin mRNA. Samples were 
analysed in triplicate and experiments repeated separately three times. * P<0.05 and 
*** P<0.0001 
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Figure 4.2 MCF7 genes expression with individual phytoestrogens. Concentrations of 
genistein and coumestrol shown to reduce cell viability also modify the expression of 
genes implicated in EMT (snail), preferential metastasis (CXCR4 and integrin α5β3) 
and osteolysis (PTHrP) in MCF7 cells. Cells were cultured with genistein or daidzein for 
24 or 72 hours prior to mRNA isolation. Gene expression was then assessed using 
cT qPCR and the DNA-binding dye SYBR green for detection of PCR products. The 
relative quantification (RQ) value for each group was calculated using CT values for 
non-treated controls normalized to the expression β-actin mRNA. Samples were 
analysed in triplicate and experiments repeated separately three times. * P<0.05, ** 
P<0.01 and *** P<0.0001versus control 
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4.3.2 Modulation of phytoestrogens effect by TGF-β on genes involved in the 
metastatic process in prostate and breast cancer cells. 
This experiment will look at the role of TGF on phytoestrogens that induced 
changes to genes expression in a microenvironment that mimic what 
phytoestrogen will encounter in this microenvironment in PC3 and MCF7 cells. 
Genes that been studied in PC3 are (Runx2, osterix and collagen type I) as the 
most abundant protein within the bone and that prostate and breast cancer cells 
bound with high affinity to this protein) and looking at (PTHrP, snail and collagen 
type I) expression in breast cancer cells (MCF7). 
TGF-β at 0.1 ng/mL for 72 hours significantly reduced PC3 Runx2 (74%, P = 
0.008) and osx (66%, P = 0.03) expression and increased collagen type I 
expression significantly (159% at P 0.02). Daidzein 10-7 M/TGF-β decrease 
Runx2 (60%, P = 0.008) and osx decreased (47%, P = <0.0001), while in 
genistein 10-6 M/TGF-β Runx2 decreased (58%, P = 0.003) and osx (77% at P= 
0.01)  after 72 hours This results of significant Runx2 reduction was opposite to 
the individual effect of these phytoestrogens in the absence of TGF-β on Runx2 
gene expression after 72 hours. TGF-β induced collagen type I expression 
reduced by PE, returning near the control levels. Also, collagen type I 
expression was less in combinations comparing to its high expression with the 
individual treatment of TGF- β (Figure 4.3). 
In MCF7 cells, treatment with TGF- β significantly increased Snail expression 
(148%, P = 0.01). Collagen type I expression also increased but not to 
significant levels (139%,  P = 0.16) while PTHrP stay lower but not to significant 
level (81%, P = 0.13). When TGF-β at 0.1 ng/mL combined with and coumestrol 
(10-5 M) for 72 hours significantly reduced the expression of the PTHrP (25%, P 
= 0.03), collagen type I (12%, P = <0.0001) and snail (33%, P = 0.008) which is 
 
80 
 
similar to the significant effect of individual genistein on both PTHrP and snail 
gene expression in the absence of TGF-β. Genistein (10-5 M) become more 
effective in the presence of TGF-β than when used individually and reduced 
PTHrP (22%, P = 0.001), collagen type I (22%, P = <0.0001) and snail (44%,P =  
0.003) significantly as shown in (Figure 4.4). 
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Figure 4.3  Transforming growth factor β (TGF-β) in PC3 cells. shown to interfere the 
effect of phytoestrogens and modify their individual action on the expression of genes 
involved in osteomimicry (Runx2) in PC3 cells. Cells were cultured with genistein or 
daidzein for 72 hours prior to mRNA isolation. Gene expression was then assessed 
using CT qPCR and the DNA-binding dye SYBR green for detection of PCR 
products. The relative quantification (RQ) value for each group was calculated using CT 
values for non-treated controls normalized to the expression β-actin mRNA. Samples 
were analysed in triplicate and experiments repeated separately three times. * P<0.05, 
** P<0.01 and *** P<0.0001versus control 
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Figure 4.4 Transforming growth factor β (TGF-β) shown to interfere the effect of 
phytoestrogens and modify their individual action on the expression of genes involved 
in bone vicious cycle (PTHrP) and metastasis process of EMT (Snail) in MCF7 cells. 
Cells were cultured with genistein or coumestrol for 72 hours prior to mRNA isolation. 
Gene expression was then assessed using CT qPCR and the DNA-binding dye 
SYBR green for detection of PCR products. The relative quantification (RQ) value for 
each group was calculated using CT values for non-treated controls normalized to the 
expression β-actin mRNA. Samples were analysed in triplicate and experiments 
repeated separately three times. * P<0.05, ** P<0.01 and *** P<0.0001versus control 
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4.3.3 Bone morphogenic protein 7 (BMP 7) modify the individual effect of 
phytoestrogens on gene expression in prostate and breast cancer cell 
lines. 
 Bone morphogenic protein 7 (BMP 7), a bone formation and remodelling factor, 
and combinations of phytoestrogens with BMP7 or TGF-β were studied. Runx2 
and integrin α5β3 expression was investigated in PC3 cells while expression of 
snail and integrin α5β3 were investigated in MCF7 cells after 72 hours to give 
phytoestrogens more time of engaging with cytokine environment containing 
BMP7 and to determine the importance of osteomimicry and the ability to initiate 
the EMT process in these cell lines.  
BMP7 reduced PC3 cell integrin α5β3 expression to significant levels (18%, P = 
0.09), while Runx2 expression was not reduced significantly by BMP7 exposure 
(79%, P = 0.70). Previously, individual Daidzein and genistein reduced Integrin 
α5β3 significantly in the absence of BMP7.In the presence of BMP7 the 
expression of Integrin α5β3 highly increased (99%, P = 0.98) but not to a 
significant level. Runx2 gene expression did not show any decrease but stayed 
on its high non-significant levels in the presence or absence of BMP7 (167%, P 
= 0.22) (Figure 4.5). 
Combining BMP7 and TGF-β at 0.1 ng/mL also had no significant effect on 
Runx2 (68%, P = 0.60) and integrin α5β3 (79%, P = 0.65) expression. Genistein 
or daidzein and BMP7 combination non-significantly increased the expression of 
Runx2 (169%, P = 0.21) and (167%, P = 0.22) and integrin α5β3, (155%, P = 
0.26) and (99%, P = 0.98) respectively, which is similar to the previous result 
with individual phytoestrogens in the absence of BMP7 (Figure 4.5). 
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In MCF7 cells, BMP7 significantly reduced integrin α5β3 expression (43%, P = 
0.009). Combining BMP7 and TGF-β also significantly reduced integrin α5β3 
expression (28%, P = 0.001). Previously, individual genistein significantly 
decreased snail expression in the absence of BMP7. In the presence of BMP7, 
genistein alters its effect and increased snail expression significantly (377%, P = 
0.009). Individual coumestrol had a similar non-significant effect in the presence 
and absence of BMP7 (131%, P = 0.76) and (85%, P = 0.31) respectively, 
neither decreased nor increased snail expression significantly. Previous 
individual genistein and coumestrol significantly reduced the expression of 
Integrin α5β3 in the absence of BMP7 (9%, P = <0.0001) and (7%, P = <0.0001) 
respectively. In the presence of BMP7, phytoestrogens genistein 10-5 M and 
coumestrol 10-5 M lost their significant effect (81%, P = 0.39) and (68%, P = 0.1) 
respectively (Figure 4.6). 
 
 
 
 
 
 
 
85 
 
 
Figure 4.5  Modification of Runx2 and Integrin α5β3 gene expression in PC3 cell line by 
BMP7. BMP7 interfere the effect of phytoestrogens and modify their individual action on 
the expression of genes involved in osteomimicry (Runx2) and metastasis process of 
EMT (Integrin α5β3) in PC3 cells. Cells were cultured with genistein or daidzein for 72 
hours prior to mRNA isolation. Gene expression was then assessed using CT qPCR 
and the DNA-binding dye SYBR green for detection of PCR products. The relative 
quantification (RQ) value for each group was calculated using CT values for non-
treated controls normalized to the expression β-actin mRNA. Samples were analysed in 
triplicate and experiments repeated separately three times. * P<0.05 versus control. 
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Figure 4.6 Modification of snail and gene expression in MCF7 cell line by 
BMP7:BMP7interfere the effect of phytoestrogens and modify their individual action on 
the expression of genes involved in metastasis process of EMT (Snail and Integrin 
α5β3) in MCF7 cells. Cells were cultured with genistein or coumestrol for 72 hours prior 
to mRNA isolation. Gene expression was then assessed using CT qPCR and the 
DNA-binding dye SYBR green for detection of PCR products. The relative quantification 
(RQ) value for each group was calculated using CT values for non-treated controls 
normalized to the expression β-actin mRNA. Samples were analysed in triplicate and 
experiments repeated separately three times. * P<0.05, ** P<0.01 and *** 
P<0.0001versus control. 
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4.4 Discussion 
The potential benefit of individual phytoestrogens is underlined by their ability to 
modify the expression of genes implicated in tumour progression when 
cytokines typical of the bone environment are absent.  Snail, a key transcription 
factor that induces integrin and cadherin expression during epithelial to 
mesenchymal transition, was suppressed by genistein and daidzein in the 
absence of TGF-β and BMP7 (Figure 4.2 A). In keeping with this, genistein and 
daidzein also reduced integrin α5β3 and CXCR4 expression (Figure 4.2 B and 
D). CXCR4 plays a major role in preferential metastasis of breast and prostate 
cancer to the skeleton, as bone marrow is the major source of CXCR4’s ligand. 
A decrease in CXCR4 expression would, therefore, be expected to reduce the 
incidence of skeletal secondaries. These pose a major therapeutic challenge 
due to the tumour promoting stimulus provided by the bone environment. 
Central to this is the binding of aberrantly expressed cell adhesion molecules, 
such as integrin α5β2, to Arginylglycylaspartic acid (RGD) containing proteins in 
the bone matrix. This sequesters tumour cells to bone, provides additional 
proliferative stimuli and promotes pro-angiogenic growth factor connective 
tissue. Growth factor (CTGF) induced angiogenesis, contributing to the 
disproportionate impact of skeletal metastases in late-stage disease (Heldin, 
Vanlandewijck & Moustakas, 2012). Decreased integrin α5β3 and CXCR4 
expression would, therefore, reduce disease progression and morbidity.  
However, it could be argued that cells would disseminate to other organs, 
delaying, rather than limiting, progression. 
While, overall, the tumour burden is augmented in the skeleton, bone tissue is 
not a supportive environment for its development, as its mineralised nature 
limits growth and lacks a dense capillary network.  This paradox is explained by 
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the ability of tumour cells to disrupt bone remodelling and, as a consequence, 
circumvent these limitations and generate a more conducive environment for 
growth. Breast cancer cells generate a developmental niche through the 
production of PTHrP, which indirectly stimulates osteoclast formation and bone 
resorption, by increasing the RANKL expression on osteoblasts and bone 
marrow stromal cells (Patel et al., 2011).  Prostate cancer, in contrast, is 
associated with an osteosclerotic response, caused by a process that is termed 
osteomimicry.  Osteomimicry forms part of the EMT, during which the tumour 
cells express transcription factors such as Runx2 that are typically restricted to 
the osteoblastic lineage (Cox et al., 2012; Jadaan, Jadaan & McCabe, 2015).  
The current data indicate that individual phytoestrogens modify the expression 
of these genes. Genistein and daidzein transiently reduced Runx2 expression in 
prostate cells and genistein significantly reduced PTHrP expression in breast 
cells. These changes would be expected to further limit the ability of skeletally 
disseminated cancer cells to survive and prosper in bone tissue, further 
reducing skeletal morbidity, such as hypercalcemia of malignancy. 
The addition of TGF-β at (0.1 ng/mL) and BMP7 at (30 ng/mL) to the culture 
environment was to construct a cytokine model which the cells would typically 
encounter in bone, and to assess whether this modified the response of the PEs. 
Interestingly, the addition of rhTGF-β was found to block the signalling of 
rhBMP7,  thus blocking the expression of genes important in bone formation 
(Ehnert et al., 2012). In contrast, according to a study by Zeisberg et al., BMP7 
was found to counteract the TGF-β signalling mechanism (Zeisberg et al., 2003). 
Transforming growth factor β, (rhTGF-β), shows an antagonist effect on 
phytoestrogen-induced changes, in combinations with daidzein and genistein. 
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The same results were observed when studying the effect on Runx2 and Osx, 
but not for collagen type I. This result suggests an important role for TGF-β on 
PE (daidzein and genistein) in early stages of metastasis, by inhibiting the 
expression of the osteomimicry genes (Runx2 and Osx) which are responsible 
for the direction of the cancer cell to the bone microenvironment in many 
cancers, including prostate cancer (Han et al., 2012). TGF-β blocks any effect of 
PE and increases collagen type I gene expression, but did not display this effect 
on Runx2 and osx, which both decreased significantly. This is contrary to the 
findings of Enhert et al., that TGF- β effectively blocks BMP7 in osteoblast, thus 
suggesting that blocking of the process of osteomimicry in cancer cells (Ehnert 
et al., 2012). Therefore, in the presence of TGF-β, daidzein and genistein, which 
increase the expression of Runx2, lost their effect on the expression of genes 
responsible for osteomimicry (Runx2 and Osx).  
The inhibitory effect of genistein on PTHrP and snail is also lost in the presence 
of TGF-β. The latter reduced the non-inhibitory effect of individual coumestrol on 
PTHrP and snail gene expression to a significant extent (Figure 4.5).This 
suggest a strong effect of TGF-β on coumestrol and genistein action presented 
in a bone microenvironment vicious cycle. 
Furthermore, low Snail expression suggest a decrease in the EMT process by 
elevating levels of epithelial phenotype, markers such as E-cadherin and 
integrin α5β3, at the primary tumour site. In contrast, TGF-β alone increased the 
expression of PTHrP, collagen type I and Snail in breast cancer cells, indicating 
a negative effect of TGF-β on the invasive, migration and proliferation of cancer 
cells which were inhibited when combined with phytoestrogens (Figure 4.5). It is 
suggested that TGF-β might be of importance on genistein action which has 
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been clear in this study results , and indicates that a relation between PEs and 
growth factors really exists (Adlercreutz, 2002). 
BMP7 has shown an inhibitory effect on the phytoestrogens daidzein and 
genistein, and increased the expression of Runx2 in prostate cancer cell lines 
(Figure 4.6). Also, BMP7 inhibited the effect of genistein and coumestrol in 
breast cancer cell lines and increase the expression of snail to a high level. This 
is opposite to what had been observed of the individual effect of genistein 
(Figure 4.7).  Individual coumestrol and genistein effects were noticeably 
greater than when combined with BMP7,and lost the significant decrease of 
integrin α5β3 (Figure 4.7). 
Here, the current results demonstrated that BMP7 interferes and abolishes the 
inhibitory effect of individual phytoestrogens (daidzein, genistein and 
coumestrol),  increases the expression of genes important in osteomimicry, 
(Runx2), EMT process (snail and Integrin α5β3) and enhances the migration of 
prostate and breast cancer cells. (Alarmo et al., 2009).  
The data summarised here sets the scene for further research and 
investigations into this new class of plant-derived compounds that are capable 
of interfering with very complicated diseases, such as prostate and breast 
cancer, and its interaction with important growth factors and cytokines, such as 
TGF-β and BMP7, that may cause further complications to the patient. 
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4.5 summary of chapter 4 results 
 
Table 4.5.1 phytoestrogens effect on expression of genes involved in metastasis in PC3 for  24h and 72h 
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Gen 
10-7 
25* 0.02  2 *** 2x10-3 2** 5x10-3 126 0.1 20*** <10
-4 
282 0.4 20*** <5x10-
4 
142 0.2 
Gen 
10-6 
30* 0.02  36 * 0.02 1** 5x10-3 3*** 10-4 11*** <10
-4 
160 0.47 11*** <2x10-
4 
13* 0.02 
Daid 
10-8 
25* 0.01  18*** <6x10-3  6** 0.01 3*** 10-4 18*** <10
-4 
179 0.29 3*** <10-4 9* 0.01 
Daid 
10-7 
117 0.55 27* 0.01 112 0.67 4*** 10-4 14*** <10
-4 
134 0.48 228*** <10-4 7* 0.04 
 
Note: “    “ and  “      “ means upregulation, down-regulation of the indicated target respectively. * P<0.05, ** P<0.01 and *** P<0.0001 
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Table 4.5.2 phytoestrogens effect on expression of genes involved in metastasis in MCF7 for 24h and 72h 
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10-6 
*** 
329 
 
 
<10-4 20** <10-4 42*** <4x10-4 37** 0.01 126 0.84 67 0.7
4 
12*** <10-4 12*** <10-4 
Gen 
10-5 
*** 
495 
 
 
<10-4 34*** <3x10-4 50** 0.01 61 0.08 179 0.3 11 0.2
9 
0*** <10-4 12*** <10-4 
Cou 
10-7 
*** 
305 
 
 
<10-4 126 0.08 53** <10-3 113 0.53 180 0.27 * 
127 
0.0
4 
0*** <10-4 14*** <10-4 
Cou 
10-6  
125 
 
 
0.45 98 0.87 23*** <10-4 90 0.64 103 0.94 94 0.4
3 
6*** <10-4 16*** <10-4 
Cou 
10-5 
46 
 
 
0.11 85 0.31 9*** <10-4 71 0.17 60 0. 39 78 0.8
6 
19*** <10-4 7*** <10-4 
 
Note: “    “ and  “      “ means upregulation, down-regulation of the indicated target respectively. * P<0.05, ** P<0.01 and *** P<0.0001 
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Table 4.5.3 TGFβ interfere the individual effect PEs action on expression of 
genes involved in osteomimicry in PC3 cells 
 
Concentration (M) Runx2 Collagen type I Osx 
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TGFβ 74** 0.008 159* 0.02 66* 0.03 
Daid 10-7 134 0.48     
TGFβ + Daid 10-7 60** 0.008 103 0.88 47*** <0.0001 
Gen 10-6 160 0.47     
TGFβ + Gen 10-6 58** 0.003 96 0.82 77* 0.01 
 
Note: “    “ and  “      “ means upregulation, down-regulation of the indicated target 
respectively. * P<0.05, ** P<0.01 and *** P<0.0001 
 
 
Table 4.5.4 TGFβ interfere the individual effect PEs action on expression of 
genes involved in bone vicious cycle in MCF7 cells 
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TGFβ 81 0.13 139 0.16 148* 0.01 
Cou 10-5 78 0.86   85 0.31 
TGFβ + Cou 10-5  25* 0.03 12*** <0.0001 33** 0.008 
Gen 10-5 11 0.29   34*** 0.0003 
TGFβ + Gen 10-5 22*** 0.001 22*** <0.0001 44** 0.003 
 
Note: “    “ and  “      “ means upregulation, down-regulation of the indicated target 
respectively. * P<0.05, ** P<0.01 and *** P<0.0001 
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Table 4.5.5 BMP7 interference the effect of individual PEs action on expression 
of genes involved in osteomimicry and metastasis process EMT in PC3 cells 
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BMP7 79 0.7 18 0.09 
BMP7+TGFβ 68 0.6 79 0.65 
10-7 134 0.48   
Daid 10-7  +BMP7 167 0.22 99 0.98 
Daid 10-7  + BMP7 + TGFβ 169 0.21 166 0.17 
Gen 10-6 160 0.47   
Gen 10-6 + BMP7 169 0.21 155 0.26 
Gen 10-6 + BMP7 + TGFβ 183 0.14 203 0.03 
 
 
Note: “    “ and  “      “ means upregulation, down-regulation of the indicated target 
respectively. * P<0.05, ** P<0.01 and *** P<0.0001 
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Table 4.5.6 BMP7 interference the effect of individual PEs action on expression 
of genes involved in metastasis process EMT in MCF7 cells 
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BMP7 186 0.37 43** 0.009 
BMP7+TGFβ 186 0.95 28*** 0.001 
Cou 10-5 85 0.31 7*** <0.0001 
Cou 10-+ BMP7 131 0.76 68 0.1 
Cou 10-5 + BMP7 + TGFβ 303 0.06 82 0.49 
Gen 10-5 34*** 0.0003 9*** <0.0001 
Gen 10-5 + BMP7 377** 0.009 81 0.39 
Gen 10-5 + BMP7 + TGFβ 547*** 0.0001 64 0.11 
 
 
Note: “    “ and  “      “ means upregulation, down-regulation of the indicated target 
respectively. * P<0.05, ** P<0.01 and *** P<0.0001 
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Chapter Five 
 Modulatory effect of IL-33 on phytoestrogen-induced changes in the 
gene expression of breast and prostate cancer cell lines  
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5.1 Introduction 
Interleukin IL-33, a member of IL-1 cytokine family, is a dual-function protein 
that acts both as an alarming extracellular cytokine and as an intracellular 
nuclear factor. Abundant nuclear expression of IL-33 in endothelial cells from 
both large and small blood vessels in most normal human tissues, as well as in 
human tumours IL-33 is constitutively expressed in epithelial barrier tissues and 
lymphoid organs, maintaining the barrier function in normal conditions, and is 
released as a danger signal upon cellular damage or stress. By binding to its 
membrane ST2 receptor, IL-33 exerts an important role in inflammation, and 
allergy, and promotes the production of large amounts of IL-5 and IL-13 as part 
of  type-2 innate immunity, IL-33 also induces the phosphorylation and 
activation of ERK1/2, JNK, p38 and PI3K/AKT signaling modules causing a 
production and release of pro-inflammatory cytokines(Hu et al., 2017; Koyasu & 
Moro, 2011).   
The IL-33/ST2 pathway augments breast cancer progression and metastasis by 
promoting intra-tumoural accumulation of immunosuppressive cells, such as 
macrophages, myeloid-derived suppressor cells (MDSCs), mesenchymal 
stromal cells (MSCs) and by decreasing innate anti-tumour immunity (Figure 
5.1). Furthermore, IL-33 was over-expressed in various cancers. A high 
expression of IL-33 was reported in colorectal cancer(CRC) tissues (Liu et al., 
2014b), and the serum of breast cancer (Lu et al., 2014), and non-small cell 
lung cancer (NSCLC) patients (Hu et al., 2013). Further studies shown that     
IL-33 is constitutively expressed to high levels in the nuclei of endothelial and 
epithelial cells in vivo and that it can be released in the extracellular space after 
cellular damage. Thus, IL-33 was suggested to function as an endogenous 
danger signal or alarmin to alert cells of the innate immune system of tissue 
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damage during trauma or infection and a full-length IL-33 does not require 
processing for biological activity (Lefrançais et al., 2012). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.1: Cellular sources and targets of IL-33. IL-33 is released from endothelial cells, 
epithelial cells and fibroblasts in response to tissue damage or mechanical stress (dotted 
arrow). After release, IL-33 functions as an alarmin and activates different types of cells , 
including Th2 cells, Tregs, basophils, mast cells, eosinophils, macrophages, dendritic cells, 
innate lymphoid cells (ILC2s), NK cells and NKT cells. These activated cells respond to IL-
33/ST2 signaling by producing both pro-inflammatory and anti-inflammatory mediators (Xu et 
al., 2017). 
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Toll-like receptors (TLRs) and other pattern recognition receptors, (PRRs), 
enhance the immune response after the recognition of conserved motifs 
expressed by pathogens. TLRs are also triggered by endogenous danger 
signals, termed danger-associated molecular patterns (DAMPs), which are 
released from the damaged host tissue after trauma or stress and may be 
considered as a signalling pathway for IL-33 (Xu et al., 2017). 
It has been reported that transgenic expression of IL-33 may activate CD8 (+) T 
cells and NK cells, and inhibit tumour growth and metastasis in B16 melanoma 
and Lewis lung carcinoma metastatic models. It has also been shown to have 
direct effects on cancer cells, activating multiple intracellular signalling 
cascades to promote stemness and inhibit chemotherapy-induced cell death. 
Thus, IL-33, through direct and in-direct actions, has an important role in 
promoting tumour progression.  Therefore, like other cytokines, IL-33 may 
modulate the response to potential therapeutic agents, leading to poorer 
outcomes. Currently, there is an absence of literature studying the effect of      
IL-33 in the presence of phytoestrogens or any other phytochemicals in breast 
and prostate cancer.  
This chapter will try to model a breast and prostate cancer environment for IL-33 
in the presence of phytoestrogens, and will attempt to study the effect of IL-33 
on phytoestrogen-induced gene expression in PC3 cells (CXCR4, Runx2, snail 
and Integrin α5β) and (CXCR4, snail and Integrin α5β) in MCF7 cells.  This 
chapter will also investigate whether phytoestrogens, will keep their individual 
beneficial effects on expression of these genes (as in Chapter Three) and will 
attempt to find a relationship between this expression and the presence of IL-33. 
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5.2 Materials and methods 
Methods used here in chapter 5 are similar to what has been mentioned in 
chapter 2 (materials and methods) for the points: 
2.5.1 RNA extraction and reverse transcription  
2.5.2 Verification of PCR primers and RT  
2.5.3 10x Tris-acetate-EDTA (TAE) buffer  
2.5.4 Real-time quantitative PCR analysis of metastatic marker expression 
2.6 Statistical analysis 
5.2.1 IL-33 Cytokine 
 
Recombinant Human IL-33 was purchased from Insight Biotechnology Limited 
(Wembley Middlesex, United Kingdom) and concentration used was 10 ng/mL 
(Choi et al., 2009). IL-33 added to two sets one for individual IL-33 for 24 and 72 
hours and one for IL-33 and phytoestrogens also for 24 and 72 hours.  
Primers used were as following: 
 
 5 -´3  ´Forward primer 3 -´5  ´Reverse primer  
Human β-actin GCGCGGCTACAGCTTCACCA TGGCCGTCAGGCAGCTCGTA 777-929 
Human Runx2 AGACCCCAGGCAGGCACAGT GCGCCTAGGCACATCGGTGA 816-972 
Human CXCR4 GCGCAAGGCCCTCAAGA GTGCGTGCTGGGCAGAGGTT 1010-1257 
Human Snail CGAGTGGTTCTTCTGCGCTA CTGCTGGAAGGTAAACTCTGGA 27-183 
Human  Integrin 
α5β3 
AATTTTACTGGCGAGCAG TTGGTGGCATGCTTCGAG 1054- 1465 
 
Table 5.1 PCR primers and their amplicons used with IL-33 experiments 
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5.3 Results 
5.3.1 IL-33 effect on phytoestrogen-induced changes in CXCR4 gene 
expression in PC3 cells 
Here in this experiment the effect of phytoestrogens in the presence of IL-33 on 
CXCR4 was studied. IL-33 alone had no significant effect on CXCR4 expression 
in either 24 or 72 hours and was (117%, P = 0.58) and (120%, P = 0.57). 
However, the suppressive effect of daidzein and genistein seen in previous 
chapters was abolished in the presence of IL-33. After 24 hours, CXCR4 
expression increased significantly in the presence of IL-33 plus daidzein (189%, 
P = 0.02) or genistein (187%, P = 0.03). After 72 hours, there was an increase in 
CXCR4 expression in both combinations (239%, P = 0.01) for IL-33 with 
daidzein and (168%, P = 0.19) for IL-33 with genistein, but this increase was 
significant only with daidzein (Figure 5.2). 
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Figure 5.2 Interleukin 33 (IL-33) prevents the inhibitory effect of phytoestrogens on 
CXCR4 in PC3 cells. Cells were cultured with genistein or daidzein for 24 or 72 hours 
prior to mRNA isolation. Gene expression was then assessed using CT qPCR and 
the DNA-binding dye SYBR green for detection of PCR products. The relative 
quantification (RQ) value for each group was calculated using CT values for non-
treated controls normalized to the expression β-actin mRNA. Samples were analysed in 
triplicate and experiments repeated separately three times. * P<0.05, ** P<0.01 and *** 
P<0.0001versus control 
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5.3.2 IL-33  has negative effect on Snail gene expression in the presence of 
phytoestrogens in PC3 cells. 
IL-33 alone had no significant effect on Snail expression at 24 and 72 hours 
(130%, P = 0.47) (170%, P = 0.15) respectively.  However, in the presence of 
IL-33 the inhibitory effect of daidzein and genistein on snail expression was lost 
and a significant increase was noted at 72 hours for daidzein (199%, P = 0.04) 
(Figure 5.3). 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.3 Interleukin 33 (IL-33) modifies the response to PE on snail expression in 
PC3 cells. Cells were cultured with genistein or daidzein for 24 or 72 hours prior to 
mRNA isolation. Gene expression was then assessed using CT qPCR and the DNA-
binding dye SYBR green for detection of PCR products. The relative quantification (RQ) 
value for each group was calculated using CT values for non-treated controls 
normalized to the expression β-actin mRNA. Samples were analysed in triplicate and 
experiments repeated separately three times. * P<0.05 versus control. 
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5.3.3 IL-33  increased Runx2 gene expression in the presence or absence of 
phytoestrogens in PC3 cells 
There was no significant inhibitory effect of IL-33 alone on Runx2 gene 
expression at 24 or 72 hours and was (156%, P = 0.13) (134%, P = 0.34) 
respectively. However, the inhibitory effect of genistein and daidzein on runx2 
expression was lost in the presence of IL-33 for genistein at 24 hours was 
significant (332%, P = <0.0001) and at 72 hour was (143%, P = 0.18)  and for 
daidzein at 24 hours was (125%, P = 0.46) and at 72 hours was (82%, P = 0.58)  
(Figure 5.4). 
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Figure 5.4 Interleukin 33 (IL-33) modifies the response to PE on runx2 expression in 
PC3 cells. Cells were cultured with genistein or daidzein for 24 or 72 hours prior to 
mRNA isolation. Gene expression was then assessed using CT qPCR and the DNA-
binding dye SYBR green for detection of PCR products. The relative quantification (RQ) 
value for each group was calculated using CT values for non-treated controls 
normalized to the expression β-actin mRNA. Samples were analysed in triplicate and 
experiments repeated separately three times. *** P<0.0001versus control. 
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5.3.4 Effect of IL-33 on phytoestrogen-induced effects on integrin 
α5β3 gene expression in prostate cancer PC3 cells. 
 
IL-33 alone decreased the expression of integrin α5β3 significantly after 72 
hours (34%, P = 0.009) which indicate for a protection against the loss of cell-
cell contact which is a known behaviour in cancer initiation for migration. IL-33 
prevented the inhibitory effect of genistein on integrin α5β3 expression and led 
to a significant increase in expression after 24 hours for genistein (452%, P = 
<0.0003) and decreased sharply after 72 hours with genistein, this might be 
related to unknown behaviour of IL-33 at these time points. On the other hand, 
the individual daidzein significant effect on integrin α5β3 gene expression 
decreased but not to a significant level (49%, P = 0.44) after 24 hours with IL-33 
(Figure 5.5). 
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Figure 5.5 Interleukin 33 (IL-33) modifies the response to PE on integrin α5β3 
expression in PC3 cells. Cells were cultured with genistein or daidzein for 24 or 72 
hours prior to mRNA isolation. Gene expression was then assessed using CT qPCR 
and the DNA-binding dye SYBR green for detection of PCR products. The relative 
quantification (RQ) value for each group was calculated using CT values for non-
treated controls normalized to the expression β-actin mRNA. Samples were analysed in 
triplicate and experiments repeated separately three times. * P<0.05 and *** P<0.0001 
versus control. 
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5.3.5 The effect of IL-33 on phytoestrogen-induced changes in CXCR4 gene 
expression in MCF7 cells. 
IL-33 alone had no significant effect on CXCR4 expression at 24 and 72 hours 
and was (63%, P = 0.053) and (120%, P = 0.65) respectively. IL-33 had no 
effect on the inhibitory action of genistein or coumestrol at 24 hours but 
prevented the inhibitory effect genistein on CXCR4 expression at 72 hours and 
was (123%, P = 0.59) and (124%, P = 0.58) respectively (Figure 5.6). 
 
Figure 5.6 Interleukin 33 didn’t interfere the inhibitory action of coumestrol and genistein on 
CXCR4 gene expression in MCF7 cells at 24 hours but modifies later responses to 
genistein on CXCR4 expression in MCF7 cells. Cells were cultured with genistein or 
coumestrol for 24 or 72 hours prior to mRNA isolation. Gene expression was then assessed 
using CT qPCR and the DNA-binding dye SYBR green for detection of PCR products. 
The relative quantification (RQ) value for each group was calculated using CT values for 
non-treated controls normalized to the expression β-actin mRNA. Samples were analysed 
in triplicate and experiments repeated separately three times.                         * P<0.05, ** 
P<0.01 and *** P<0.0001versus control 
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5.2.6 IL-33 prevented the inhibitory effect of genistein on snail expression at 
later stage in MCF7 cells 
IL-33 has been tested here to observe whether there is any effect on EMT 
related gene (snail) expression with and without phytoestrogens. It has been 
noticed that IL-33, alone, significantly decreased snail expression at 72 hours 
(38%, P = 0.02). Also, IL-33 prevented the inhibitory effect of genistein at 72 
hours (81%, P = 0.45) and decreased it at 24 hours but not to a significant level 
compared to individual genistein, whereas the effect with coumestrol was not 
changed (Figure 5.7). 
 
 
 
 
 
 
 
 
 
 
Figure 5.7  Interleukin 33 (IL-33) modifies the later response to genistein on snail 
expression in MCF7 cells. Cells were cultured with genistein or coumestrol for 24 or 72 
hours prior to mRNA isolation. Gene expression was then assessed using CT qPCR and 
the DNA-binding dye SYBR green for detection of PCR products. The relative quantification 
(RQ) value for each group was calculated using CT values for non-treated controls 
normalized to the expression β-actin mRNA. Samples were analysed in triplicate and 
experiments repeated separately three times. * P<0.05 versus control. * P<0.05 and *** 
P<0.0001 
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5.2.7 IL-33 modifies the response to phytoestrogen-induced changes in integrin 
α5β3 expression in MCF7 cells.    
IL-33 significantly decreased integrin α5β3 expression at 72 hours (53%, P = 
0.01) and 24 hours but was not significant decrease (24%, P = 0.07).  IL-33 
modified the response to genistein and coumestrol and prevented the decrease 
in expression at 24 hours (158%, P = 0.13) and (65%, P = 0.30), however the 
same significant decrease at 72 hours remained for genistein and coumestrol 
(Figure 5.8). 
 
Figure 5.8 Interleukin 33 in MCF7 cells and Integrin α5β3 gene expression.    
Interleukin 33 (IL-33) modifies the early response to genistein and coumestrol on 
integrin expression in MCF7 cells.  Cells were cultured with genistein or coumestrol for 
24 or 72 hours prior to mRNA isolation. Gene expression was then assessed using 
CT qPCR and the DNA-binding dye SYBR green for detection of PCR products. The 
relative quantification (RQ) value for each group was calculated using CT values for 
non-treated controls normalized to the expression β-actin mRNA. Samples were 
analysed in triplicate and experiments repeated separately three times. * P<0.05 and 
*** P<0.0001 
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5.3 Discussion 
IL-33 has been studied mainly for its role in Th2 immunity and Th2-related 
diseases, such as asthma, atopic dermatitis, and anaphylaxis. IL-33 is released 
from a variety of tissues as a pro-inflammatory cytokine (Villarreal & Weiner, 
2014). Serum levels of IL-33 and sST2 in breast cancer patients were 
significantly higher than in healthy women, and it is thought to be a prognostic 
marker in several cancers (Lu et al., 2014). ST2 was initially shown to be 
selectively expressed on Th2, but not Th1 or regulatory T cells (Treg). More 
studies have shown that IL-33 can activate murine dendritic cells directly driving 
polarisation of naïve T cells towards a Th2 phenotype, and it can act directly on 
Th2 cells to increase secretion of Th2 cytokines such as IL-5 and IL-13. 
Moreover, IL-33 can also act as a chemo-attractant for Th2 cells. Limited 
studies have addressed the role of IL-33/ST2 signaling on anti-tumour immune 
responses, tumour growth and or metastasis. However, recent studies revealed 
that ST2 negative mice with mammary tumour have attenuated tumour growth 
and metastasis, with increased circulating levels of pro-inflammatory cytokines 
and activated NK and CD8+ T cells. Therefore, IL-33 may be an important 
mediator in tumour escape from immune control and in tumour angiogenesis 
and thus warrants further investigation (Miller, 2011). 
Moreover, IL-33 and its receptor sST2 were found to have a significant 
correlation with serum VEGF, which indicates an association of  IL-33 and sST2 
with angiogenesis (Lu et al., 2014). Zhang et al. also indicated that tumour 
derived IL-33 enhanced the recruitment of myeloid cells. such as macrophages, 
that secrete VEGF to promote tumour angiogenesis and metastasis by 
remodelling the tumour microenvironment, rather than by modifying the intrinsic 
propensity of tumour cells to invade, migrate, or undergo EMT (Zhang et al., 
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2017). IL-33 has been shown to enhance liver inflammation and fibrosis, thus, 
providing a substrate for hepatobiliary tumour development.  By affecting 
multiple pro-tumour processes, directly and indirectly, IL-33, through AKT and 
Yes-associated proteins, promotes oncogene-induced cholangiocarcinoma 
(CCA) in mice (Yamada et al., 2015). Jovanovic et al. found that exogenously 
administrated IL-33 enhanced primary 4T1 (mouse breast cancer) growth and 
inhibited innate anti-tumour immunity (Jovanovic et al., 2012). In gastric cancer, 
IL-33 enhanced invasion and migration in a dose-dependent manner (Yu et al., 
2015). 
It has been observed that serum levels of IL-33 are higher in patients with ER-
positive tumours, suggesting that the IL-33/ST2 axis may be involved in 
hormone receptor signaling (Liu et al., 2014a). Hormone therapy is a first-line 
treatment for ER-positive breast cancer, with tamoxifen as the most widely used 
anti-oestrogen drug. Haiyan and his team indicated an important function of    
IL-33 in producing an endocrine resistance of breast cancer patients by 
promoting expressions of stem cell genes, including ALDH1A3, OCT4, NANOG 
and SOX2, promoting tumourigenesis, leading to the development of breast 
cancer stem cells. In clinical breast cancer patients, higher serum IL-33 levels 
predict tumour recurrence, while increased IL-33 expression in cancer cells 
predicts tamoxifen resistance, due to less ER expression (Hu et al., 2017). 
 IL-33 was studied herein to find whether it modified the effect of phytoestrogens 
on expression of genes important in osteomimicry (Runx2), cell migration 
(CXCR4), EMT (snail and integrin α5β3). In prostate cancer, interleukin-33 
abolishes the significant reduction of CXCR4 gene expression caused by 
individual genistein and daidzein and increases it to higher levels. Also, IL-33 
113 
 
affects the expression of runx2 that increased with both individual treatment of 
IL-33 and when combined with phytoestrogens but not to a significant levels 
only increased significantly with genistein at 24 hours. Also IL-33 increased 
snail expression but was significant only with daidzein at 72 hours and 
increased integrin α5β3 expression and was significant only when combined 
with genistein after 24 hours. Thus, in the presence of IL-33 the potentially 
beneficial effect of PEs on osteomimicry, preferential metastasis and epithelial 
transition is lost.   
The data on the role of IL-33 in cancer progression is limited, especially with 
regard to the function mediated in human breast cancer cells (Liu et al., 2014a). 
IL-33 was used to inhibit the individual effect of genistein and coumestrol on 
important genes in metastasis and cell migration. IL-33 modified the individual 
effect of PEs, and altered their effect by upregulation of CXCR4, snail and 
integrin α5β3 gene expression. This data suggests that the presence or 
expression of IL-33 in the breast cancer environment have a role in promoting 
the epithelial-mesenchymal transition process and cell migration. 
There was a difference between individual genistein phytoestrogen and when 
combined with IL-33 in both prostate and breast cancer cell lines at 24 and 72 
hours. This might be the availability of oestrogen receptors ER and that IL-33 
and its reaction with its receptor ST2 affect the ER signaling of genistein and 
abolish its effect. A further detailed investigation should elucidate this activity.      
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In conclusion, IL-33 might have an important role in both prostate and breast 
cancers. Due to the shortage of literatures regarding the cross-talk between    
IL-33 and phytoestrogens in cancers, particularly breast and prostate cancers, 
this study tried to add to the evidence that IL-33 plays a non-protective role, 
enhancing the progression of the disease and worsening the situation, both in 
vitro and in vivo. Further expansion of research on IL-33 interaction with the 
phytochemical are necessary if we are attain a sound knowledge of the function 
of phytoestrogens. 
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5.4 summary of chapter 5 results 
 
Table 5.4.1 IL-33 modification to the response to PEs in PC3 cells at 24h and 72h 
 
Concentration 
(M) 
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24h 72h 24h 72h 
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IL-33 117 0.58 120 0.57 130 0.47 170 0.15 
Daid 10-7 112 0.67 4*** 0.0001 117 0.55 27* 0.01 
Daid 10-7 + IL-33 189 * 0.02 239* 0. 01 173 0.1 199* 0.04 
Gen 10-6  1** 0.005 3*** 0.0001 30* 0.02 36* 0.02 
Gen 10-6  + IL-33 187* 0.03 168 0.19 119 0.7 198 0.0505 
 
 
Concentration 
(M) 
Runx2 Integrin α5 
24h 72h 24h 72h 
% of 
control  
P 
Value 
% of 
control  
P 
Value 
% of 
control  
P 
Value 
% of 
control  
P 
 Value 
IL-33 156 0.13 134 0.34 131 0.64 34** 0.009 
Daid 10-7 14*** 0.0001 134 0.48 *** 
228 
0.0001 7* 0.04 
Daid 10-7 + IL-33 125 0.46 82 0.58 49 0.44 51* 0.04 
Gen 10-6  *** 
11 
0.0001 160 0.47 *** 
11 
0.0002 13* 0.02 
Gen 10-6  + IL-33 *** 
332 
 
<0.000
1 
143 0.18 *** 
452 
0.0003 68 0.14 
 
Note: “    “ and  “      “ means upregulation, down-regulation of the indicated target 
respectively. * P<0.05, ** P<0.01 and *** P<0.0001 
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Table 5.4.2 IL-33 modification to the response to PEs in MCF7 cells at 24h and 72h 
 
Concentration (M) 
 
CXCR 4 Snail Integrin α5 
24h 72h 24h 72h 24h 72h 
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IL-33 
63 
0. 053 120 0.65 98 0.95 38* 0.02 24 0.07 53* 0.01 
Cou 10-5 9*** <10-4 71 0.17 46 0.11 85 0.31 19*** <10-4 7*** <10-4 
Cou 10-5 + IL-33 22*** <10-4 124 0.58 48 0.12 99 0.98 65 0.30 54* 0.02 
Gen 10-5 42*** 4x10-4 37* 0.01 *** 
329 
<10-4 20*** <10-4 12*** <10-4 12*** <10-4 
Gen 10-5 + IL-33 36** 0.002 123 0.59 52 0.18 81 0.45 158 0.13 29*** 7x10-4 
 
 
Note: “    “ ,  “      “  and “         “ means upregulation, down-regulation and little or no regulation of the indicated target respectively. * P<0.05, ** P<0.01 
and *** P<0.0001 
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6. General discussion 
Of particular interest in relation to human health are the class of compounds 
known as the phytoestrogens, which are comprised of various groups of non-
steroidal oestrogenic compounds that are broadly distributed within the plant 
kingdom. There is an increasing body of evidence that consumption of some of 
these plants or their molecules could be an additive effective tool to prevent and 
treat several diseases associated with ageing, metabolism, malignant 
transformation and cardiovascular disease (Sirotkin & Harrath, 2014).  
Soybeans, along with other phytoestrogen- rich food such as legumes, are rich 
with phytochemicals, are processed into various food products for digestibility, 
taste and bioavailability of nutrients and bioactive compounds (Zaheer & 
Humayoun Akhtar, 2017). The oestrogenic compounds (i.e. isoflavones) in 
phytoestrogens are found in the form of glucosides, malonylglucosides, 
acetylglucosides and aglycones. In the gut, the isoflavone glycosides present in 
soy products are deglycosylated by β- glucosidases in the small intestine. The 
metabolism of soy isoflavones by bacteria varies among individuals. Inter-
individual differences in phytochemical metabolism may be affected by gut 
microbial identity and activity, and stability and variation in concentrations of 
endogenous compounds that may modulate biotransformation pathways. 
Furthermore, gut bacterial modification of soy isoflavones results in  metabolites 
that differ in biological activity from the main compounds (Miura et al., 2016). 
Thus, human gut microflora have been shown to employ metabolic activities on 
isoflavones that influence bioavailability and bioactivity (Turner, Thomson & 
Shaw, 2003) 
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Oestrogens impact on the growth and functioning of female and male 
reproductive tissue, support the skeletal and central nervous system, contribute 
to cardio-protective effects, and protect against colon cancer and skin aging. In 
the light of the numerous effects on the human body of oestrogens, it is not 
unusual to consider the importance of phytoestrogens for human health. They 
are perceived as a more natural way to complement medical health care, and 
many women turn to phytoestrogens as an alternative to hormone replacement 
therapy (HRT) in order to circumvent undesirable side effects, such as 
increased risk of breast and endometrial cancer and irregular bleeding (Ososki 
& Kennelly, 2003b). 
One may ask why the role of phytoestrogens in prostate carcinogenesis should 
be studied when prostate growth and development are regulated by 
testosterone. However, epidemiological studies indicate a lower rate of prostate 
and breast cancers in Asian communities than in Western communities, which is 
explainable in terms of diet, chiefly the regular intake of soy phytoestrogens 
(Adjakly et al., 2015). The phenolic ring structures of isoflavones enable these 
phytochemical compounds to bind oestrogen receptors (ER) and mimic 
oestrogen (E2). In addition to genistein and daidzein binding ER, it is with a 
lower affinity when compared with estradiol, and with greater affinity for ERβ 
than for ERα. Furthermore, phytoestrogens have been described as acting like 
natural selective ER modulators (SERMs) at various tissue sites throughout the 
body (Lund et al., 2004). 
The results here indicate that phytoestrogens (genistein and daidzein) have a 
significant effect on reducing prostate cancer cell growth. Genistein and 
daidzein can bind to ERβ and mimic the action of oestrogens. This binding 
between these phytoestrogens and the receptor could partly explain the anti-
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cancer effects of these molecules and their impact as a focus for prostate 
pathology research (Adjakly et al., 2015; Mentor-Marcel et al., 2001). 
Furthermore, Piccolella et al. indicated that genistein in prostate cancer shows 
antiproliferative action through ERβ (Piccolella et al., 2014). In vitro studies 
demonstrate a role for phytoestrogens (tectorigenin and irigenin) in controlling 
prostate cancer cell numbers by inhibiting proliferation through cell cycle 
regulation. These compounds would reduce cell numbers and increase the 
ability of antiandrogens to induce cell death in prostate cancer cells and prove 
that many other phytoestrogens beside genistein and daidzein have a 
significant effect on prostate cancer cell inhibition (Morrissey et al., 2004). 
Another study on prostate cancer cells showed that genistein directly inhibits Akt 
and NF-κB pathways, which leads to activation of apoptosis (Russo et al., 2016). 
Many studies suggest that phytoestrogens like genistein may compete with, and 
prevent, endogenous oestrogens from binding to the oestrogen receptor (ER), 
thus inhibiting cellular proliferation and promoting differentiation. Also, several 
clinical studies suggest high soy consumption may facilitate prostate cancer 
prevention, but its role as therapy for an established tumour is conflicting 
(Masko, Allott & Freedland, 2013). Results of other studies indicate the 
functional beneficial effects of coumestrol in promoting apoptosis of human 
prostate cancer cells PC3, thus reducing cell numbers. The study suggests a 
mechanism for coumestrol action in prostate cancer that an intrinsic apoptotic 
pathways and inhibition of PI3K/AKT and activation of MAPKs (ERK1/2 and JNK) 
cell signaling may be involved. These mechanistic conclusions support the 
suggestion that coumestrol has anti-cancer effects on prostate cancer cells, 
affecting their viability and mitochondrial functions by a significant loss of 
mitochondrial membrane potential. Additionally, cleavage of caspase-3 and -9, 
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which are apoptotic proteins associated with mitochondria, also altered in 
response to coumestrol. Furthermore, coumestrol caused mitochondrial 
dysfunction resulting in an increase in ROS production in PC3 and LNCaP cells, 
although that finding contradicts the current results, which concluded that 
coumestrol did not suppress cell proliferation in prostate cancer cells, but rather 
enhanced it (Lim et al., 2017) 
In breast cancer, phytoestrogens have been studied to see their effect on cell 
viability. Phytoestrogens (genistein and coumestrol) have the greatest 
significant effect on breast cancer cell growth reduction in my studies, whereas 
daidzein acted as a promoter ofr breast cancer cell growth. It has been found 
that dietary phytoestrogen intake during adolescence may be associated with a 
decreased risk of adult breast cancer. This finding has significant implications 
for breast cancer prevention, since diet is a potentially modifiable determinant 
(Thanos et al., 2006). Furthermore, it has been observed that phytoestrogens 
(genistein, glycitein, daidzein,O-Desmethylangolensin (O-Dma), coumestrol and 
equol) shown a potent inhibitory effect on MDA-MB-231 breast cancer cell 
invasion, while lignans exerted a minimal effect in matrigel experiments (Magee, 
McGlynn & Rowland, 2004). 
This study produced outcomes similar to those of Wang et al., which suggested 
that genistein above 10−5 M inhibited growth of MCF7 cells, while below this 
concentration genistein stimulated growth  (Wang, Sathyamoorthy & Phang, 
1996). The proposed mechanism for phytoestrogen effects in breast tumour 
cells is that the set of genes upregulated by ERβ activation promote cell cycle 
progression and consequently suppress proliferation, while activation of ERα 
appears to do largely the opposite (Patisaul & Jefferson, 2010). There is some 
epidemiological evidence of increased phytoestrogen intake being associated 
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with a reduced risk of breast cancer, but it is inconsistent.  Unlike soy flour 
which had no effect, soy extracts and purified isoflavones caused growth 
stimulation of MCF7 cells transplanted into ovariectomised athymic mice 
(Velentzis et al., 2008). It has been suggested that dietary consumption of 
phytoestrogens, including coumestrol, reduces the risk of breast cancer.  
However, phytoestrogens also share antagonistic characteristics that affec the 
risk of developing breast cancer (Zafar, Singh & Naseem, 2017).  In a previous 
study on MCF7 cells, phytoestrogens seem to have had the effect of increasing 
cell numbers, which contradicted the findings of my own study, interestingly; 
however, this increase is not the result of a stimulation of proliferation, butis the 
consequence of the inhibition of the rate of apoptosis. These results support the 
hypothesis that phytoestrogens may stimulate the progression of an existing 
tumour (Schmidt, Michna & Diel, 2005). Another suggestion was that genistein 
phytoestrogen treatment resulted in a greater cell survival in MCF7 cells, 
probably due to its oestrogenic activity through its binding to ERα. However, the 
interaction of genistein with the ERβ perhaps suggests that the most important 
part of the study was that of phytoestrogens in combination. Furthermore, these 
results suggest that the anti-oestrogenic activity of phytoestrogens was 
established by a mechanism similar to tamoxifen or ICI 182,780, leading to a 
reduction in cell proliferation (Collins, McLachlan & Arnold, 1997; Pons et al., 
2016) . Furthermore, Mário L de Lemos concluded that genistein and daidzein 
may stimulate existing breast tumour growth and antagonise the effects of 
tamoxifen. He warned women with breast cancer that they should be aware of 
the risks of possible tumour growth when taking soy products. Thus, adding 
phytoestrogens will return with negative effect on the HRT as the study here 
indicated an increase in most of the genes expression in prostate and breast 
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cancers, thus adding to the evidence of that adding phytoestrogen has a 
negative effect on HRT. which is an indication of the bad effect of 
phytoestrogens and IL33 in combinations(de Lemos, 2001).  
Various studies have focused on the effect of single phytoestrogens in isolation 
and have mostly ignored the effect that these phytochemicals may have in 
combination with one another. It is important to examine these compounds in 
suitable combinations, correlated with their origin in the environment, 
metabolism, and presence in vivo. It has been suggested that when 
environmental oestrogens in general are found in combination with one another, 
they may either cancel each other out, resulting in no physiological effect a 
synergistic oestrogenic impact, or a synergistic anti-oestrogenic effect on 
oestrogen-sensitive pathways (Willard & Frawley, 1998). After studying the 
effect of individual phytoestrogens to establish effective concentrations in 
experiment model, a further investigations applied to study the impact of these 
PEs in combination. Phytoestrogens, when combined, lost their inhibitory effect 
on cell viability for both cell lines. Cell numbers increased and no synergistic 
effect was observed. This suggests the antagonist behaviour of each 
phytoestrogen, and could be a mechanism of ER-dependent and independent 
antagonistic interactions, including kinase activation, that work against each 
other and cause loss of growth inhibition. The current results both differ from, 
and agree ,  the small number of studies that have examined  combinations 
(Dong et al., 2013; Kumar et al., 2011; Willard & Frawley, 1998).  It has been 
suggested that a combination of phytoestrogens had no stimulatory effect at all, 
or may be antagonistic, depending on the precise combination of PEs (Mousavi 
& Adlercreutz, 1992; Willard & Frawley, 1998) and these findings concur with 
the current study. 
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When studying the motility and migration in both prostate and breast cancer 
cells, the effect of phytoestrogens on PC3 cells’ rate of closure was found to be 
minimal and only daidzein showed an enhancement of the closure rate. On the 
other hand, in MCF7 cells, genistein and daidzein displayed no effect on motility 
rate, while coumestrol decreased the scratch width at in the early stages. 
Moreira et al. noticed a decrease in the proliferation rate of breast cancer cells 
and motility when phytoestrogens were used. This is in contrast to other current 
findings i.e., that for most phytoestrogens there was no effect (Moreira et al., 
2012). Genistein and other phytochemicals inhibited the proliferation of prostate 
cancer cells and also tumour growth in mice, via modulation of Gli1 expression. 
It was also shown that genistein inhibited Hedgehog (Hh) signalling in prostate 
cancer cells, thus suppressing their stem cell properties and reducing cell 
motility by maintaining epithelial properties.  It has been found also that daidzein 
metabolites, such as equol,  were significantly more active than daidzein, 
implying that there was a similarly enhanced effect of daidzein and its 
metabolites on regulation of in vivo invasion and migration in breast tumours 
(Bao et al., 2014). This may be an area for further exploration. Also, both R- and 
S- equol enantiomers were found to inhibit the growth of breast cancer cell line 
MDA-MB-231 and the prostate cancer cell lines LNCap, and to inhibit the 
invasion of MDA-MB-231 and PC3 cancer cells through matrigel. Furthermore, 
S-equol was unable to prevent DNA damage in MCF7 cells but R- eqoul was 
protective in the same cell line, suggesting a variation in the chemoprotective 
properties of equol in vivo (Magee et al., 2006).  
The data from the current study clearly shows differences between the effects of 
individual phytoestrogens on prostate and prostate cell viability and motility. 
While individual PEs significantly reduced cell numbers, this reduction was lost 
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when they were in combination. As a result, these observations add more 
indefinite characteristics to PE and their use in prostate and breast cancer 
patients. Hence, further and deeper investigations are required to determine the 
precise clinical use of PE. 
After studying the effect of PEs on prostate and breast cancer viability and 
motility, there followed a further investigation of their effect on gene expression 
levels. The genes that were studied have important roles in promoting cell 
migration, EMT process, osteomimicry and bone vicious cycles. Two of the PEs 
that had been shown previously to affect a significant reduction in cell numbers 
were deployed to study the effect of these phytoestrogens on the genes 
responsible for cell migration, epithelial-mesenchymal transition EMT and 
metastasis such as in snail, CXCR4 and integrin α5β. Genistein and coumestrol 
displayed no significant effect, the only effect was that of Gen 10-5M  on the 
PTHrP gene expression in breast cancer cells after 72 hours, suggesting no 
roles for these phytoestrogens on bone vicious cycle and thus more TGF-β and 
osteoclast differentiation and more osteolysis.  
Runx2 expression was studied as a marker of osteomimicry in prostate cancers. 
The results indicated a favourable impact of phytoestrogens on genes related to 
metastasis EMT and osteomimicry. The results also indicated that the 
phytoestrogens under study (genistein, daidzein and coumestrol) resist 
transformation into mesenchymal stem cells and detachment from the primary 
site instead of heading to its next target organ. It has also been demonstrated 
that genistein is capable of inhibiting invasion through a variety of mechanisms 
in multiple cell types (Pavese, Farmer & Bergan, 2010). The studies here agree 
with the latest studies that have explained that phytoestrogens, particularly 
genistein, may have the potential to inhibit cancer metastasis by particularly 
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adjusting the EMT process via diverse signaling pathways and their effect on 
gene expression under study in prostate and breast cancer has been 
demonstrated (Lee, Hwang & Choi, 2016). It can be concluded that there was a 
clear and important effect of the phytoestrogens under investigation on the gene 
expression in prostate and breast cancer cells. As discussed earlier, individual 
phytoestrogens affect cell viability that may involve both ERα and ERβ 
dependent and independent signaling pathways. These signaling routes may 
apply to the same effect of phytoestrogens on genes that consider very 
important and associated with vital cell pathology and morphology like cell 
migration, EMT process, osteoclast differentiation, vicious cycle and osteolysis 
through the same signaling pathways. Therefore, further and deeper studies are 
needed in order to investigate phytoestrogens, possible active receptors or 
channels, their connection to gene expression and their effect on cell 
pathological activity. 
The study tried to model the environment that prostate and breast cancer cells 
may face in bone. To investigate this, a three cytokines: TGF-β, BMP7 and      
IL-33 has been used. In prostate cancer TGF-β appear to abolish the activity of 
phytoestrogens, decrease the gene expression of Runx2 and Osx, and increase 
collagen type I expression. This suggests that TGF-β promotes a late stage of 
osteomimicry in prostate cancer in the presence of phytoestrogens, compared 
to the same phytoestrogens when studied individually. In breast cancer, TGF-β 
significantly decreased the expression of PTHrP, collagen type I and snail, 
which suggests that TGF-β causes less EMT, reduced vicious cycles and 
osteomimicry, and plays a protective role, which is opposite to its role as a 
promoter of tumourigenesis in breast cancer. In conclusion, TGF-β can have 
strong tumour suppressive properties in the earlier stages of the disease, while 
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having a tumour-promoting effect at more advanced stages. Thus, treatments 
that target TGF-β too early in the disease process may be detrimental, and the 
timing of certain therapies needs careful consideration. Thus, phytoestrogens 
may play a dual role in prostate and breast cancer in the presence of TGF-β 
(Principe et al., 2014). 
 The results show that BMP7 in prostate cancer enhances the progression of the 
disease progression through interference with the action of phytoestrogens by 
increasing the expression of Runx2 and integrin α5β3. In breast cancer cells, 
BMP7 showed an increase in snail and integrin α5β3 expression that might 
suggest an acceleration of tumour burden and of a late stage EMT type 
response.  However, other studies suggest that not all BMPs induce EMT, and 
some appear to promote MET, reducing the aggressive properties of tumour 
cells. In murine mammary epithelial cells , BMP-7 was not able to induce EMT, 
whereas TGF-β could suggest a protective role for BMP7, which is opposite to 
results suggested here (Zabkiewicz et al., 2017). 
In the IL-33 prostate cancer model experiment, the addition of phytoestrogens 
results in increased gene expression (CXCR4, snail, Runx2 and integrin α5β3), 
causing  IL-33 to prevent or cancel the effect of phytoestrogens when added 
individually. These results might suggest that IL-33 had a detrimental effect at 
the early stage of tumours. Furthermore, the IL-33 effect on breast cancer in the 
presence of phytoestrogens also showed an ablation of their effect on CXCR4 
and snail expression, but didn’t affect expression of integrin α5β, compared to 
the individual phytoestrogens. These results in breast cancer may suggest that 
IL-33 has a detrimental effect by promoting cell migration and metastasis, which 
increases the tumour burden at the early stages. The data on the role of IL-33 in 
cancer progression is limited, especially the data concerning the function 
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mediated in human breast cancer cells (Liu et al., 2014a).  For this reason, 
intensive and detailed studies are recommended for IL-33 involvement in cancer 
diseases, and efforts need to be made to elucidate its important role in the 
presence of phytoestrogens. This study contributes to the literature in a small 
way, but further study will be required if we are to grasp the whole picture. 
There were positive and negative aspects to this study. The in vitro results add 
some data to the contemporary studies of phytoestrogens; but, on the negative 
side, the phytoestrogens were not studied in vivo and conjoined with the in vitro  
results to achieve a better understanding of their effect. I hope in future to study 
further the effect of phytoestrogens on other cancer cell lines and to include in 
vivo studies on animals. There will be a greater focus on the in vivo outcomes, 
and, hopefully, more advanced molecular techniques applied.  
In conclusion, this study showed that phytoestrogens are effective when 
administered individually but lose this effect when they are combined. Also, 
growth factors should be taken in considerations if recommend phytoestrogens 
as hormone replacing therapy. Hence, before considering phytoestrogens as a 
supplement, clinicians must take into consideration the overall profile of 
phytoestrogens before administration. Furthermore, what applied to the 
epidemiological effect of phytoestrogens in one area may not apply in others. 
Hence, administrating phytoestrogens at an early stage might be of more benefit 
than at a later stage. Finally, intensely focussed studies of phytoestrogens are 
most certainly required, and must include further agents and factors involved in 
the progression and pathology of tumours. 
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Downregulation of CXCR4 gene expression in breast and prostate 
cancer cells by phytoestrogens (genistein, daidzein and coumestrol)
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Bone is one of the most preferential metastatic target sites for cancers including breast and prostate. Up to 70%
of breast or prostate cancer will develop bone metastasis. The consequences of bone metastasis are always
devastating. Metastatic process include proliferation and invasion of cancer cells at primary site, intravasation ,
migration in the circulation and extravasation, arrest in bone marrow, egress from central sinus and attachment
to bone surfaces and colonization of cancer cells and bone destruction(Zhang, Ma & Fan, 2010).
Bone metastases may be associated with bone destruction (osteolytic lesions) or alternatively osteosclerosis in
which increased osteoblast activity predominates (prostate cancer). Breast cancer patients tend to have a mixed
pattern of metastases,40% producing lytic metastases, 40% mixed lytic and sclerotic and 20% sclerotic(Iddon,
Byrne & Bundred, 1999).
There is ample evidence that the movement of cancer cells through the body is not random and that different
types of cancer cells have different destinations. A specific set of genes that mediate bone metastasis has been
described. Cells over-expressing IL-11, MMP-1, connective tissue growth factor (CTGF), CXCR-4 (Fig,1) and
osteopontin (OPN), were highly metastatic to the bone in vivo(Sierra, 2005).
Dietary soy has been shown in mice to inhibit prostate tumour growth through inhibition of cell proliferation,
increased apoptosis, and reduced microvessel density [3]. Epidemiology studies of Asian women indicate that
consumption of a traditional diet high in soy confers significant protection against breast cancer(Hsu et al.,
2009).
Breast (MCF-7) and prostate (PC3) cancer cells were cultured in 25cc Flask with the phytoestrogens genistein
(10-5M and 10-6M) and coumestrol( 10-5M, 10-6M and 10-7M) for breast cancer MCF-7 cells and genistein (10-6M
and 10-7M) and daidzein ( 10-7M and 10-8M) for prostate cancer cells (PC3). Each concentration was incubated
with the cells individually into two timepoint groups 24 and 72 hours in 37oC and 5% CO2.
RNA extracted from the cells using GenElute Mammalian total RNA miniprep kit(sigma-aldrich) then cDNA was
prepared by M-MLV reverse transcriptase (sigma-aldrich) to be used as a template for quantitation real-time
PCR to quantify the CXCR4 gene expression in Breast and prostate cancer treated with phytoestrogens. CXCR4
primers used were Eurofins 5’-GCG CAA GGC CCT CAA GAC CA-3’ (Forward) and 5’-GTG CGT GCT GGG CAG
AGGTT-3’ (Reverse).
Quantitative real-time PCR thermal cycler(Applied Biosystems) used to detect the CXCR4 gene expression in
breast and prostate cancer cells using SYBER®Green JumpStart™ Taq ReadyMix™ (Sigma-aldrich) and internal
Reference Dye (Sigma-aldrich) in 48 reaction-plate(Applied Biosystems).
1- see the effect of individual phytoestrogens on breast and prostate cancer viability.
2- see the effective phytoestrogen combinations on cell viability.
3- look at the expression of factors involved in preferential metastasis ,CXCR4, using  quantitative  
real-time PCR.
4- look at the expression of genes involved in osteomimicry or disease progression PTHrP, Runx2  
and Collagen I.
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Figure 2: showing the materials and methods used to detect CXCR4 gene expression
Figure 1:showing the role of CXCR4 role in cancer metastasis
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Figure 3:CXCR4 gene expression  in MCF-7 cells after treatment with phytoestrogens for 24 and 72 hours showing 
significant  decrease in CXCR4 gene expression for both timepoints 24 and 72 hours but not for coumestrol 
concentrations after 72 hours.    P<0.05
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Figure 4: CXCR4 gene expression  in PC3 cells after treatment with phytoestrogens for 24 and 72 hour 
showing significant  decrease in CXCR4 gene expression for both timepoints 24 and 72 hours . P<0.05
Figure 5: showing the effect of phytoestrogens on Runx2 and Collagen I genes expression in 
prostate cancer PC3 cells with PTHrP and Collagen I genes expression in breast cancer (MCF-7) cells   
Conclusions 
 In the whole these effects may reduce preferential metastasis and could lead to decreased tumour
burden and morbidity as a consequence.
 More investigations are required to further understand the functional importance of these and other
genes to support the potential therapeutic usage of phytochemicals in breast and prostate cancer.
 Looking further into the role of other factors enhance these factors such as growth factors and the role of
phytoestrogens on this enhancement.
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